[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"GE Healthcare Biosciences\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":307},{"warningLetters":4,"total":306},[5,30,53,76,97,122,141,163,187,206,226,244,266,288],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},2952,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-01T05:00:00Z\">12\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdermacare-biosciences-ltd-617910-12012021\">DermaCare Biosciences, LTD.\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rich Butler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DermaCare Biosciences, LTD.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 W. Atlantic Avenue Suite #05\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Delray Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33444\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rich@dermacarepkg.com\"> rich@dermacarepkg.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: December 1, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your websites at the Internet addresses https:\u002F\u002Fwww.easyrapidnow.com\u002F and https:\u002F\u002Fwww.dermacarepkg.com\u002F, on February 2, 2021, on September 20, 2021, and on October 22, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F, https:\u002F\u002Fwww.facebook.com\u002Fdermacarepkg\u002F, and https:\u002F\u002FInstagram.com\u002Feasyrapidcovidtestkits where you direct consumers to your website, https:\u002F\u002Fwww.easyrapidnow.com, to purchase your products. The FDA has observed that your website offers for sale the Easy Rapid Now COVID-19 Nasal Swab Antigen Test (Colloidal Gold) (hereinafter referred to as “COVID-19 Test”) in the United States. Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The COVID-19 Test is offered for sale and distributed to consumers in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Your website, https:\u002F\u002Fwww.easyrapidnow.com\u002F, as well as social media websites, include statements that indicate that your firm’s COVID-19 Test is intended for screening or diagnosis\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of COVID-19, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Mass Surveillance. Protect Classrooms, Workplaces, and Other Populations.” [https:\u002F\u002Feasyrapidnow.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“I was part of a surveillance screening at work. I was feeling symptoms and I took the EasyRapidNow™ test. It showed “positive”. I went for a PCR test and sure enough, it confirmed I had COVID. These really work!” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\u003C\u002Fli>\n\t\u003Cli>“Routine Coronavirus surveillance gives you an early warning of infection, allowing targeted measures to be taken to stop the spread.” [https:\u002F\u002Feasyrapidnow.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“These EasyRapidNow™ tests will be super easy for you to perform and I have firsthand experience. My wife came home Monday evening with a cough and not feeling well. In 15 minutes, we confirmed that she was positive, and we were able to take the appropriate precautions. She works in a doctor’s office and was able to get a PCR test the next day, which confirmed that she was positive. My son and I tested negative and have no symptoms so far. Two days later my son and I tested again, and I was positive, he was negative. We are grateful to have the early warning. This type of early warning will assist you in keeping your workplace and employees safer resulting in fewer business interruptions.” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\u003C\u002Fli>\n\t\u003Cli>“Rapid detection of SARS-CoV-2 nucleocapsid antigen in less than 15 minute [sic]” [https:\u002F\u002Feasyrapidnow.com\u002Fwp-content\u002Fuploads\u002FEasyRapidNow-Brochure_Ja25_U.S.pdf]\u003C\u002Fli>\n\t\u003Cli>COVID-19 Nasal Swab Tests Available Now! Test results in as little as 5 minutes! Simple Easy Fast Affordable! Scan QR Code to buy now!” [https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s websites include a disclaimer that your tests “enable[] surveillance screening at a population level” are “not intended for diagnostic use or home use.”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, these disclaimers are inconsistent with the statements identified above on your firm’s websites that indicate these tests are intended to be used to identify individuals infected with COVID-19 so that individual decisions can be made based on the test results (e.g., quarantine or confirmatory testing). Furthermore, FDA has observed that your business offers for sale the COVID-19 Test directly to consumers in the United States. Based on the statements identified on your website above and your sale of these tests directly to consumers, the FDA has determined that your test is intended for diagnosis of COVID-19 including screening for COVID-19 in asymptomatic individuals without known exposure with the intent of making individual decisions based on the test results (e.g., who may return or what protective measures to take on an individual basis).\u003C\u002Fp>\n\n\u003Cp>We also note that your social media LinkedIn site, https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacarepackaging-private-label\u002F, displays a large FDA logo at the top right of the page alongside information about your COVID-19 test and other products. The FDA logo is for the official use of the FDA and not for use on private sector materials.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised) \u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>” provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send emails&nbsp;\u003C\u002Fstrong>\u003Cstrong>to\u003C\u002Fstrong> \u003Cstrong>COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and\u003Cbr>\n&nbsp; &nbsp; Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>______________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Screening for COVID-19 is looking for occurrence at the individual level even if there is no individual reason to suspect infection such as a known exposure. Examples of screening include testing plans developed by a workplace to test all employees returning to the workplace regardless of exposure or signs and systems and testing plans developed by a school to test all students and faculty returning to the school regardless of exposure or signs and symptoms, with the intent of using the results to determine who may return or what protective measures to take on an individual basis. Diagnostic testing for COVID-19 is also looking for occurrence at the individual level but is performed when there is a particular reason to suspect that an individual may be infected. Examples of diagnostic testing include testing symptomatic individuals presenting to their healthcare provider, testing individuals who indicate that they were exposed to an individual with a confirmed or suspected case of COVID-19, and testing all individuals present at an event where an attendee was later confirmed to have COVID-19. \u003Cem>See\u003C\u002Fem> COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Surveillance testing is primarily used to gain information at a population level, rather than an individual level. Surveillance testing may be a random sampling of a certain percentage of a specific population to monitor for increasing or decreasing prevalence and determining the population effect from community interventions such as social distancing. An example of surveillance testing is a testing plan developed by a State Public Health Department to randomly select and sample 1% of all individuals in a city on a rolling basis to determine local infection rates and trends. \u003Cem>See\u003C\u002Fem> COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, \u003Cem>available at\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRich Butler\n\nRecipient Title\n\nManaging Director\n\nDermaCare Biosciences, LTD.\n\n301 W. Atlantic Avenue Suite #05\n\nDelray Beach, FL 33444\n\nUnited States\n\nrich@dermacarepkg.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: December 1, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your websites at the Internet addresses https:\u002F\u002Fwww.easyrapidnow.com\u002F and https:\u002F\u002Fwww.dermacarepkg.com\u002F, on February 2, 2021, on September 20, 2021, and on October 22, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F, https:\u002F\u002Fwww.facebook.com\u002Fdermacarepkg\u002F, and https:\u002F\u002FInstagram.com\u002Feasyrapidcovidtestkits where you direct consumers to your website, https:\u002F\u002Fwww.easyrapidnow.com, to purchase your products. The FDA has observed that your website offers for sale the Easy Rapid Now COVID-19 Nasal Swab Antigen Test (Colloidal Gold) (hereinafter referred to as “COVID-19 Test”) in the United States. Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe COVID-19 Test is offered for sale and distributed to consumers in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nYour website, https:\u002F\u002Fwww.easyrapidnow.com\u002F, as well as social media websites, include statements that indicate that your firm’s COVID-19 Test is intended for screening or diagnosis4 of COVID-19, including:\n\n“Mass Surveillance. Protect Classrooms, Workplaces, and Other Populations.” [https:\u002F\u002Feasyrapidnow.com\u002F]\n\n“I was part of a surveillance screening at work. I was feeling symptoms and I took the EasyRapidNow™ test. It showed “positive”. I went for a PCR test and sure enough, it confirmed I had COVID. These really work!” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\n\n“Routine Coronavirus surveillance gives you an early warning of infection, allowing targeted measures to be taken to stop the spread.” [https:\u002F\u002Feasyrapidnow.com\u002F]\n\n“These EasyRapidNow™ tests will be super easy for you to perform and I have firsthand experience. My wife came home Monday evening with a cough and not feeling well. In 15 minutes, we confirmed that she was positive, and we were able to take the appropriate precautions. She works in a doctor’s office and was able to get a PCR test the next day, which confirmed that she was positive. My son and I tested negative and have no symptoms so far. Two days later my son and I tested again, and I was positive, he was negative. We are grateful to have the early warning. This type of early warning will assist you in keeping your workplace and employees safer resulting in fewer business interruptions.” [https:\u002F\u002Feasyrapidnow.com\u002Ftestimonials]\n\n“Rapid detection of SARS-CoV-2 nucleocapsid antigen in less than 15 minute [sic]” [https:\u002F\u002Feasyrapidnow.com\u002Fwp-content\u002Fuploads\u002FEasyRapidNow-Brochure_Ja25_U.S.pdf]\n\nCOVID-19 Nasal Swab Tests Available Now! Test results in as little as 5 minutes! Simple Easy Fast Affordable! Scan QR Code to buy now!” [https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacare-packaging-private-label\u002F]\n\nYour firm’s websites include a disclaimer that your tests “enable[] surveillance screening at a population level” are “not intended for diagnostic use or home use.”5 However, these disclaimers are inconsistent with the statements identified above on your firm’s websites that indicate these tests are intended to be used to identify individuals infected with COVID-19 so that individual decisions can be made based on the test results (e.g., quarantine or confirmatory testing). Furthermore, FDA has observed that your business offers for sale the COVID-19 Test directly to consumers in the United States. Based on the statements identified on your website above and your sale of these tests directly to consumers, the FDA has determined that your test is intended for diagnosis of COVID-19 including screening for COVID-19 in asymptomatic individuals without known exposure with the intent of making individual decisions based on the test results (e.g., who may return or what protective measures to take on an individual basis).\n\nWe also note that your social media LinkedIn site, https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fdermacarepackaging-private-label\u002F, displays a large FDA logo at the top right of the page alongside information about your COVID-19 test and other products. The FDA logo is for the official use of the FDA and not for use on private sector materials.6 Such use may send a misleading message that the FDA favors or endorses your products. Unauthorized use of the FDA logo may violate federal law and subject those responsible to civil and\u002For criminal liability.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised) 7” provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send emails to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and\n\nRadiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n______________________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Screening for COVID-19 is looking for occurrence at the individual level even if there is no individual reason to suspect infection such as a known exposure. Examples of screening include testing plans developed by a workplace to test all employees returning to the workplace regardless of exposure or signs and systems and testing plans developed by a school to test all students and faculty returning to the school regardless of exposure or signs and symptoms, with the intent of using the results to determine who may return or what protective measures to take on an individual basis. Diagnostic testing for COVID-19 is also looking for occurrence at the individual level but is performed when there is a particular reason to suspect that an individual may be infected. Examples of diagnostic testing include testing symptomatic individuals presenting to their healthcare provider, testing individuals who indicate that they were exposed to an individual with a confirmed or suspected case of COVID-19, and testing all individuals present at an event where an attendee was later confirmed to have COVID-19. See COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, available at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2.\n\n5 Surveillance testing is primarily used to gain information at a population level, rather than an individual level. Surveillance testing may be a random sampling of a certain percentage of a specific population to monitor for increasing or decreasing prevalence and determining the population effect from community interventions such as social distancing. An example of surveillance testing is a testing plan developed by a State Public Health Department to randomly select and sample 1% of all individuals in a city on a rolling basis to determine local infection rates and trends. See COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2, available at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u002Fcovid-19-test-uses-faqs-testing-sars-cov-2.\n\n6 FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\n\n7 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","DermaCare Biosciences, LTD.","dermacare-biosciences-ltd-617910-12012021","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdermacare-biosciences-ltd-617910-12012021","2026-10-26T08:08:23.165889+00:00","Warning Letter","Issued","2021-12-21","617910","Medical Devices","Rich Butler","2026-08-20T02:18:28.987+00:00","2021-12-01",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},452,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-30T04:00:00Z\">10\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025\">Owen Biosciences, Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-11\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Donald R. Owen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Owen Biosciences, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7053 Revenue Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baton Rouge\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70809-4918\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-11\u003C\u002Fp>\u003Cp>October 30, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Owen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\u003C\u002Fp>\u003Cp>During the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\u003C\u002Fp>\u003Cp>In your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\u003C\u002Fli>\u003Cli>A detailed description of the method you establish to test for benzene in finished products prior to release.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\u003Cbr>o Validated stability-indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Review of production and control records to ensure completeness and accuracy (21 CFR 211.192).\u003C\u002Fli>\u003Cli>Adequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\u003C\u002Fli>\u003Cli>Appropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Performance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failed Commitment to Recall Contaminated Drug Lot\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong> communicated that it would voluntarily recall the product containing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor \u003Cstrong>(b)(4)\u003C\u002Fstrong> recalled the product before it expired.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-11\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nDr. Donald R. Owen\n\nRecipient Title\n\nChief Executive Officer\n\nOwen Biosciences, Inc.\n\n7053 Revenue Drive\n\nBaton Rouge, LA 70809-4918\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-11\nOctober 30, 2025\nDear Dr. Owen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Owen Biosciences, Inc., FEI 1000132299, at 7053 Revenue Drive, Baton Rouge, from March 25 to 27, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 10, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications for drug products prior to release (21 CFR 211.160(b) and 211.165(a)).\nYour firm manufactures various topical over-the-counter (OTC) drug products, including those containing the active ingredient benzoyl peroxide. There is a known degradation mechanism of benzoyl peroxide, under certain conditions, to form benzene, a known carcinogen. Your firm failed to establish scientifically sound and appropriate finished product specifications and failed to conduct benzene testing on your OTC topical drug products prior to release. For example, you manufactured and released at least (b)(4) lots of the (b)(4) 2.5% benzoyl peroxide acne lotion without testing for benzene. FDA laboratory analysis of one lot of (b)(4) 2.5% benzoyl peroxide acne lotion your firm manufactured and distributed yielded excessive benzene levels of more than 20 parts per million (ppm). You failed to ensure that your drug products do not contain unacceptable benzene impurity levels.\nDuring the inspection, you informed our investigator that a retain sample of the FDA-tested lot as well as other lots manufactured of the (b)(4) 2.5% benzoyl peroxide acne lotion were sent to a contract testing laboratory (CTL) to conduct impurity and assay testing.\nIn your response, you mention that you will use a CTL to conduct benzene testing on the above-mentioned drug product. However, it is not clear if benzene testing will be performed on all lots prior to release. Your response also states that you are not aware of any FDA guideline on benzene testing, but FDA has alerted drug manufacturers of products at risk for presence of benzene that they should be testing those drug products for benzene. For more information see https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fpharmaceutical-quality-resources\u002Ffda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs.\nYour response is inadequate because it does not detail any retrospective risk assessments (e.g., the actions that you will take) should any of the lots sent to your CTL for testing yield unacceptable benzene impurity levels. Further, your response lacks information that your CTL is qualified to test your drug products for benzene.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug product before a lot disposition decision.\nA detailed description of the method you establish to test for benzene in finished products prior to release.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all lots of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each lot of benzoyl peroxide products that are currently on the U.S. market within expiry. If the testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nYour stability program was not adequate to ensure that the OTC drug products you manufacture maintain their identity, strength, quality, purity, and safety throughout their shelf lives. For example, full shelf-life studies were not conducted for the entire stated expiry period. Additionally, the studies performed lacked adequate identity, microbiological, and impurities testing.\nYour response is inadequate because it fails to include sufficient details on your stability program, including how you will ensure adequate ongoing stability testing with scientific justification. Additionally, it does not include a retrospective risk assessment or information on how you will ensure marketed drug products meet stability specifications throughout shelf life.\nIn your response to this letter, provide:\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include but not be limited to:\no Validated stability-indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative lots of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint). Given that benzene is a known degradant of benzoyl peroxide and FDA analysis yielded excessive levels of benzene in your drug product, include benzene testing at each stability timepoint.\nAll procedures that describe these and other elements of your remediated stability program.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) is inadequate. Your QU did not provide adequate oversight for the manufacture of your OTC drug products. For example, your QU failed to ensure:\nReview of production and control records to ensure completeness and accuracy (21 CFR 211.192).\nAdequate written procedures to document and investigate any unexplained discrepancy or failure of a batch or any of its components to meet any specifications (21 CFR 211.22(d); 21 CFR 211.192).\nAppropriate change control procedures were followed related to drug product manufacturing (21 CFR 211.22(d)).\nPerformance of periodic (i.e., at least annual) product review (21 CFR 211.180(e)).\nIn your response, you state that you will address nonconforming products by quarantining the products and taking action to eliminate detected nonconformity. You also state that you will “follow the annual review of products,” identify nonconforming products, and make any necessary adjustments with supporting documentation.\nYour response is inadequate. You do not adequately detail how your quality function plans to improve its oversight of manufacturing quality. You also fail to assess the effects that your insufficient QU oversight had on product quality.\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help with implementing quality systems and risk-management approaches to meet the requirements of CGMP regulations in 21 CFR 210 and 211.\nFailed Commitment to Recall Contaminated Drug Lot\nFDA sampled and tested one lot of Benzoyl Peroxide Acne Lotion that is used as part of the (b)(4) Acne System Kit. On March 4, 2025, FDA held a teleconference with the drug product distributor, (b)(4), to recommend removal of this product lot from the U.S. market because it contained excessive benzene impurity levels of more than 20 ppm. During that call and again on March 5, 2025, (b)(4) communicated that it would voluntarily recall the product containing the (b)(4) Benzoyl Peroxide Acne Lotion that FDA tested. However, neither Owen Biosciences, Inc. nor (b)(4) recalled the product before it expired.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to adequately address this matter may lead to regulatory or legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when considering the award of contracts.\nFailure to address violations may be cause for FDA to withhold issuance of Export Certificates. Any violations of CGMP requirements may also be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000132299 and ATTN: Daniel W. Brisker.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Owen Biosciences, Inc.","owen-biosciences-inc-710275-10302025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowen-biosciences-inc-710275-10302025","2026-10-26T08:09:39.713108+00:00","2025-11-25","710275","Drugs Over-the-Counter Drugs","Dr. Donald R. Owen","2026-08-19T13:26:35.546+00:00","VIA Electronic Mail","320-26-11","2025-10-30",{"id":54,"raw":55,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},1450,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2024-05-21T13:20:00Z\">05\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-30T04:00:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakan-biosciences-inc-654674-04302024\">Akan Biosciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division I","CGMP\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","CGMP\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mukesh NMI Kumar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Akan Biosciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>610 Professional Drive, Ste 103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gaithersburg\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20879-3460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 30, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>24-654674\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kumar,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Akan Biosciences, Inc., located at 610 Professional Drive, Ste 103; Gaithersburg, MD 20879-3460 from September 20-30, 2022. During the inspection, an FDA investigator documented your manufacture of an adipose derived, stromal vascular fraction (SVF) cellular product for allogenic use with the brand name Ayama™ (hereinafter, also referred to as “your product”). The product’s labeling indicates it is sterile. You and your distributor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have distributed this product to practitioners and medical facilities throughout the United States.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and after the inspection, including information on your website, https:\u002F\u002Fakanbio.com\u002Fayama\u002F, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your website at https:\u002F\u002Fakanbio.com\u002Fayama\u002F (last visited April 2024), your product is an injectable product intended to “repair, reconstruct and replace your skin tissue”. Because these intended uses indicate that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. Your product is also a drug under section 201(g)(1)(C) of the FD&amp;C Act because it is intended to affect the structure or any function of the body. Your product is also a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the adipose tissue related to its utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>In addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your product is not intended to perform the same basic function or functions of adipose tissue in the recipient as in the donor, such as cushioning and support for other tissues, including the skin and internal organs, storing energy in the form of lipids, and insulating the body, among other functions. Using your product for the repair, reconstruction, and replacement of skin tissue, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because your product does not meet all the criteria in 21 CFR 1271.10(a), and Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, your product is regulated as a drug as defined in section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\u003C\u002Fp>\n\n\u003Cp>Be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, an FDA investigator documented significant violations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) from 21 CFR 1271 and issued under the authority of Section 361 of the PHS Act [42 U.S.C. § 264]. Further, FDA investigators documented evidence of significant violations from current good manufacturing practice (CGMP) requirements, including violation of section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 210 and 211.\u003C\u002Fp>\n\n\u003Cp>The violations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. Additional violations were noted upon further review of the records collected during the inspection. The violations, involving 585 vials of product manufactured between May 2021 and April 2022 from three donors, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>Failure to test a specimen from a donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]\u003C\u002Fstrong>. For example, FDA has identified human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) as relevant communicable disease agents [21 CFR 1271.3(r)], and donors of HCT\u002FPs must be tested for such agents to adequately and appropriately reduce the risk of transmission of relevant communicable disease. The donor specimens collected from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> were not tested for the antibody to hepatitis B core antigen (anti-HBc) and HIV-1, HCV, and HBV by the nucleic acid test (NAT) method. Such donors were not tested to adequately and appropriately reduce the risk of transmission of these diseases because NAT testing can detect evidence of infection at a significantly earlier stage than is possible under other tests. These donors were determined eligible on 3\u002F30\u002F2022 and 3\u002F31\u002F2022, respectively.\u003C\u002Fp>\n\n\u003Cp>2. \u003Cstrong>Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor or up to seven days before or after recovery [21 CFR 1271.80(b)]\u003C\u002Fstrong>. For example, HCT\u002FPs were recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, however a donor specimen for testing was collected from the donor on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, which is not within the required timeframe for collection of a specimen for testing.\u003C\u002Fp>\n\n\u003Cp>3. \u003Cstrong>Failure to test using appropriate FDA-licensed, approved or cleared donor screening tests, in accordance with the manufacturer’s instructions, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases [21 CFR 1271.80(c)]\u003C\u002Fstrong>. For example, the specimens for communicable disease testing, collected from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, were tested for the antibody to human immunodeficiency virus, types 1 and 2 (anti-HIV-1\u002F2), hepatitis B surface antigen (HBsAg), the antibody to hepatitis C virus (anti-HCV), and \u003Cem>Treponema pallidum\u003C\u002Fem> using test kits that were not FDA-licensed, approved, or cleared for donor screening. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F30\u002F2022. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F31\u002F2022.\u003C\u002Fp>\n\n\u003Cp>4. \u003Cstrong>Failure to screen a donor of cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)(1)]\u003C\u002Fstrong>. For example:\u003Cbr>\na) Your Form, DS-01-02 (Version 1.0) \"Donor Screening Questionnaire,” is used as a relevant medical record to determine donor eligibility and was used to screen donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. However, the form does not address certain risk factors for relevant communicable disease agents and diseases, including, for example, a donor’s risk of having West Nile Virus (WNV), among other risk factors.\u003C\u002Fp>\n\n\u003Cp>The following provides examples of conditions and behaviors that increase a donor’s relevant communicable disease risk. You should determine to be ineligible any potential donor who exhibits one or more of the following conditions or behaviors:\u003C\u002Fp>\n\n\u003Cp>i. Men who have had sex with another man in the preceding 5 years.\u003Cbr>\nii. Persons who have engaged in sex in exchange for money or drugs in the preceding 5 years. Your questionnaire only asks whether the donor has had “sexual contact with a prostitute or anyone else who takes money or drug or other payment for sex” in the past 12 months.\u003Cbr>\niii. Persons who have been in juvenile detention, lock up, jail or prison for more than 72 consecutive hours in the preceding 12 months.\u003Cbr>\niv. Persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday.\u003Cbr>\nv. Persons who have had a medical diagnosis or suspicion of WNV infection.\u003Cbr>\nvi. Persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\u003Cbr>\nvii. Persons who have been treated for or had syphilis within the preceding 12 months.\u003Cbr>\nviii. Persons who are at increased risk for Creutzfeldt-Jakob Disease (CJD) due to receiving a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or having one or more blood relatives diagnosed with CJD.\u003Cbr>\nix. Persons with a medical diagnosis of Zika Virus (ZIKV) in the past 6 months.\u003Cbr>\nx. Persons who have engaged in sex within the past 6 months with a person who has residence in, or travel to, an area with an increased risk for ZIKV transmission.\u003Cbr>\nxi. Persons who have had a diagnosis with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\u003Cbr>\nxii. Persons who have had intimate contact with a xenotransplantation product recipient.\u003C\u002Fp>\n\n\u003Cp>b) A review of records for donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> found that the donor did not complete a “Donor Screening Questionnaire” and was not screened for almost all risks of relevant communicable disease agents or diseases. From 4\u002F2022 to 7\u002F2022, you distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials of Ayama™ that had been manufactured from 5\u002F27\u002F2021 to 4\u002F4\u002F2022 from adipose tissue recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>5. \u003Cstrong>Failure to clearly identify an HCT\u002FP that is in quarantine pending completion of a donor-eligibility determination and failure to ship HCT\u002FPs with the required accompanying records for which the donor eligibility determination has not been completed [21 CFR 1271.60(b) and (c)]\u003C\u002Fstrong>. For example, your firm distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials&nbsp;of Ayama™ to \u003Cstrong>(b)(4)\u003C\u002Fstrong> physician\u002Fclinic locations in \u003Cstrong>(b)(4)\u003C\u002Fstrong> shipments between 4\u002F6\u002F2022 and 7\u002F5\u002F2022. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials were part of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials of Ayama™ manufactured from 5\u002F27-28\u002F2021 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> batches, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials total) from adipose tissue recovered from donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. Donor screening and donor testing had not been completed for donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>; therefore, a donor-eligibility determination had not been documented. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of Ayama were not clearly identified as quarantined and were not accompanied by records stating that the product must not be implanted, transplanted, infused, or transferred until completion of donor eligibility determination.\u003C\u002Fp>\n\n\u003Cp>6. \u003Cstrong>Failure to ship in quarantine a pre-distribution shipment of HCT\u002FPs between establishments for which the pre-established criteria designed to prevent communicable disease transmission have not been documented as being met [21 CFR 1271.265(b)]\u003C\u002Fstrong>. For example, your firm delivered \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of Ayama™ (part of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch vials manufactured between 3\u002F31\u002F2022 and 4\u002F4\u002F2022 from adipose tissue recovered from donors \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>) to your distributor on 5\u002F11\u002F2022 that were not shipped in quarantine to prevent improper release. The products had not been determined to be available for distribution, as described in 21 CFR 1271.265(c), as there was no documentation that the pre-established criteria designed to prevent communicable disease transmission had been met.\u003C\u002Fp>\n\n\u003Cp>7. \u003Cstrong>Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]\u003C\u002Fstrong>. For example, your firm has not validated the manufacturing process for the adipose tissue product, Ayama™, with respect to identity, strength, quality and purity.\u003C\u002Fp>\n\n\u003Cp>8. \u003Cstrong>Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]\u003C\u002Fstrong>. For example,\u003Cbr>\na) You have not performed environmental monitoring of the aseptic processing area in association with each production run. You process batches on \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. However, SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Version 3, Effective date: August 8, 2020) indicates that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> plates” sampling (i.e., contact plates and settle plates) for evaluation of viable microbial contamination of the biosafety cabinet will be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Infrequent monitoring during production of the subject drug product may preclude identification of potential microbial contaminants that could adulterate your product.\u003C\u002Fp>\n\n\u003Cp>b) Your incubation conditions of \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates used as contact plates and settle plates for environmental monitoring is not appropriate for the detection of viable microbial contamination. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Version 3, Effective date: August 8, 2020) indicates that settle and contact plates should be incubated at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours. Incubation at \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature for \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours may exclude detection of certain microbial contaminants.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter dated 10\u002F25\u002F2022, which provides a response and corrective actions to FDA’s inspectional observations (FDA-483). We have reviewed the corrective actions outlined in the response. We also acknowledge your voluntary product recall of Ayama™, initiated on 09\u002F29\u002F2022, as well as your commitment to correct firm operations and\u002For procedures involving donor eligibility (including donor screening\u002Ftesting); product quarantine; equipment calibration\u002Finspection; and labeling controls. However, we have determined that the response is inadequate to address our concerns regarding the above-noted violations as indicated below.\u003C\u002Fp>\n\n\u003Cp>21 CFR 211.100(a) requires written procedures for the production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Process validation studies determine whether \u003Cstrong>(b)(4)\u003C\u002Fstrong> state of control has been established while routine monitoring of process performance attributes determines whether control is maintained. Establishment of appropriate attributes and validation of processing method(s) of your sterile, allogeneic\u002Fnon-autologous, non-family related, HCT\u002FP product, Ayama,™ to be completed, approved, and documented prior to implementation of manufacturing operations, is essential for assuring product quality over the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>According to your voluntary product recall documentation, you initiated a voluntary recall based upon available information regarding your product (i.e., associated deficiencies in donor screening processes affecting three batches sourced from two donors), although you “believe that no specific concerns existed for the safety of the product”. Your response to the FDA-483 states that you believe “the corrective and preventive actions taken by [you] adequately address the inspectional observations.” Regarding your responses to observations 4 and 5 (shipping under quarantine) and observation 7 (procedures appropriate to meet core CGTP requirements), we acknowledge that you have updated your donor eligibility determination criteria and procedures. These updated documents will be reviewed and verified during the next inspection of your establishment. However, your response does not provide sufficient information as well as corrective\u002Fpreventative actions such as:\u003C\u002Fp>\n\n\u003Cp>a) Your response lacks detail about remaining product on hand outside the recalled product and its disposition. Please identify all finished product produced, on-hand, and shipped as well as your intended disposition of this product.\u003C\u002Fp>\n\n\u003Cp>b) Your revised process validation report for Ayama lacks significant documentation to assure that the product has the identity, strength, purity, and quality it purports or is represented to possess. For example, it lacks donor eligibility information as well as full, proper validation (with approved protocol[s]) and approval of your processing methods (including test method suitability) for your sterile, HCT\u002FP product - Ayama™ in order to ensure your processing method:\u003Cbr>\n• reduces the risk of transmission of communicable disease by an HCT\u002FP (i.e., sterility); and\u003Cbr>\n• does not cause contamination or cross-contamination during processing; and prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations. This letter notifies you of our findings and provides you an opportunity to address them. You should take prompt action to correct any violations and prevent their recurrence. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: orabioinspectionalcorrespondence@fda.hhs.gov (Cc: Jason.Abel@fda.hhs.gov, please include firm name and FEI # within email subject line). If you have any questions, please contact Jason D. Abel via email.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMichael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMukesh NMI Kumar\n\nRecipient Title\n\nPresident\n\nAkan Biosciences, Inc.\n\n610 Professional Drive, Ste 103\n\nGaithersburg, MD 20879-3460\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division I\n\nUnited States\n\nApril 30, 2024\n\nWARNING LETTER\n\n24-654674\n\nDear Mr. Kumar,\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Akan Biosciences, Inc., located at 610 Professional Drive, Ste 103; Gaithersburg, MD 20879-3460 from September 20-30, 2022. During the inspection, an FDA investigator documented your manufacture of an adipose derived, stromal vascular fraction (SVF) cellular product for allogenic use with the brand name Ayama™ (hereinafter, also referred to as “your product”). The product’s labeling indicates it is sterile. You and your distributor, (b)(4), have distributed this product to practitioners and medical facilities throughout the United States.\n\nInformation and records gathered prior to, during, and after the inspection, including information on your website, https:\u002F\u002Fakanbio.com\u002Fayama\u002F, reflect that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or a condition in humans. For example, according to your website at https:\u002F\u002Fakanbio.com\u002Fayama\u002F (last visited April 2024), your product is an injectable product intended to “repair, reconstruct and replace your skin tissue”. Because these intended uses indicate that your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, your product is a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. Your product is also a drug under section 201(g)(1)(C) of the FD&C Act because it is intended to affect the structure or any function of the body. Your product is also a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nAkan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all the criteria in 21 CFR 1271.10(a). Specifically, your product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the adipose tissue related to its utility for reconstruction, repair, or replacement.\n\nIn addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your product is not intended to perform the same basic function or functions of adipose tissue in the recipient as in the donor, such as cushioning and support for other tissues, including the skin and internal organs, storing energy in the form of lipids, and insulating the body, among other functions. Using your product for the repair, reconstruction, and replacement of skin tissue, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nTherefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because your product does not meet all the criteria in 21 CFR 1271.10(a), and Akan Biosciences, Inc. does not qualify for any exception in 21 CFR 1271.15, your product is regulated as a drug as defined in section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)] and a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\n\nBe advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product.\n\nAdditionally, during the inspection, an FDA investigator documented significant violations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) from 21 CFR 1271 and issued under the authority of Section 361 of the PHS Act [42 U.S.C. § 264]. Further, FDA investigators documented evidence of significant violations from current good manufacturing practice (CGMP) requirements, including violation of section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR 210 and 211.\n\nThe violations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. Additional violations were noted upon further review of the records collected during the inspection. The violations, involving 585 vials of product manufactured between May 2021 and April 2022 from three donors, include, but are not limited to, the following:\n\n1. Failure to test a specimen from a donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]. For example, FDA has identified human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) as relevant communicable disease agents [21 CFR 1271.3(r)], and donors of HCT\u002FPs must be tested for such agents to adequately and appropriately reduce the risk of transmission of relevant communicable disease. The donor specimens collected from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C) were not tested for the antibody to hepatitis B core antigen (anti-HBc) and HIV-1, HCV, and HBV by the nucleic acid test (NAT) method. Such donors were not tested to adequately and appropriately reduce the risk of transmission of these diseases because NAT testing can detect evidence of infection at a significantly earlier stage than is possible under other tests. These donors were determined eligible on 3\u002F30\u002F2022 and 3\u002F31\u002F2022, respectively.\n\n2. Failure to collect a donor specimen for testing for relevant communicable diseases at the time of recovery of cells or tissue from the donor or up to seven days before or after recovery [21 CFR 1271.80(b)]. For example, HCT\u002FPs were recovered from donor (b)(6), (b)(7)(C) on (b)(6), (b)(7)(C), however a donor specimen for testing was collected from the donor on (b)(6), (b)(7)(C), which is not within the required timeframe for collection of a specimen for testing.\n\n3. Failure to test using appropriate FDA-licensed, approved or cleared donor screening tests, in accordance with the manufacturer’s instructions, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents or diseases [21 CFR 1271.80(c)]. For example, the specimens for communicable disease testing, collected from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C), were tested for the antibody to human immunodeficiency virus, types 1 and 2 (anti-HIV-1\u002F2), hepatitis B surface antigen (HBsAg), the antibody to hepatitis C virus (anti-HCV), and Treponema pallidum using test kits that were not FDA-licensed, approved, or cleared for donor screening. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F30\u002F2022. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F31\u002F2022.\n\n4. Failure to screen a donor of cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)(1)]. For example:\n\na) Your Form, DS-01-02 (Version 1.0) \"Donor Screening Questionnaire,” is used as a relevant medical record to determine donor eligibility and was used to screen donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C). However, the form does not address certain risk factors for relevant communicable disease agents and diseases, including, for example, a donor’s risk of having West Nile Virus (WNV), among other risk factors.\n\nThe following provides examples of conditions and behaviors that increase a donor’s relevant communicable disease risk. You should determine to be ineligible any potential donor who exhibits one or more of the following conditions or behaviors:\n\ni. Men who have had sex with another man in the preceding 5 years.\n\nii. Persons who have engaged in sex in exchange for money or drugs in the preceding 5 years. Your questionnaire only asks whether the donor has had “sexual contact with a prostitute or anyone else who takes money or drug or other payment for sex” in the past 12 months.\n\niii. Persons who have been in juvenile detention, lock up, jail or prison for more than 72 consecutive hours in the preceding 12 months.\n\niv. Persons who have had a past diagnosis of clinical, symptomatic viral hepatitis after their 11th birthday.\n\nv. Persons who have had a medical diagnosis or suspicion of WNV infection.\n\nvi. Persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\n\nvii. Persons who have been treated for or had syphilis within the preceding 12 months.\n\nviii. Persons who are at increased risk for Creutzfeldt-Jakob Disease (CJD) due to receiving a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or having one or more blood relatives diagnosed with CJD.\n\nix. Persons with a medical diagnosis of Zika Virus (ZIKV) in the past 6 months.\n\nx. Persons who have engaged in sex within the past 6 months with a person who has residence in, or travel to, an area with an increased risk for ZIKV transmission.\n\nxi. Persons who have had a diagnosis with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\n\nxii. Persons who have had intimate contact with a xenotransplantation product recipient.\n\nb) A review of records for donor (b)(6), (b)(7)(C) found that the donor did not complete a “Donor Screening Questionnaire” and was not screened for almost all risks of relevant communicable disease agents or diseases. From 4\u002F2022 to 7\u002F2022, you distributed (b)(4) vials of Ayama™ that had been manufactured from 5\u002F27\u002F2021 to 4\u002F4\u002F2022 from adipose tissue recovered from donor (b)(6), (b)(7)(C).\n\n5. Failure to clearly identify an HCT\u002FP that is in quarantine pending completion of a donor-eligibility determination and failure to ship HCT\u002FPs with the required accompanying records for which the donor eligibility determination has not been completed [21 CFR 1271.60(b) and (c)]. For example, your firm distributed (b)(4) vials of Ayama™ to (b)(4) physician\u002Fclinic locations in (b)(4) shipments between 4\u002F6\u002F2022 and 7\u002F5\u002F2022. The (b)(4) vials were part of (b)(4) batch vials of Ayama™ manufactured from 5\u002F27-28\u002F2021 ((b)(4) batches, (b)(4) batch vials total) from adipose tissue recovered from donor (b)(6), (b)(7)(C). Donor screening and donor testing had not been completed for donor (b)(6), (b)(7)(C); therefore, a donor-eligibility determination had not been documented. The (b)(4) vials of Ayama were not clearly identified as quarantined and were not accompanied by records stating that the product must not be implanted, transplanted, infused, or transferred until completion of donor eligibility determination.\n\n6. Failure to ship in quarantine a pre-distribution shipment of HCT\u002FPs between establishments for which the pre-established criteria designed to prevent communicable disease transmission have not been documented as being met [21 CFR 1271.265(b)]. For example, your firm delivered (b)(4) vials of Ayama™ (part of (b)(4) batch vials manufactured between 3\u002F31\u002F2022 and 4\u002F4\u002F2022 from adipose tissue recovered from donors (b)(6), (b)(7)(C) and (b)(6), (b)(7)(C)) to your distributor on 5\u002F11\u002F2022 that were not shipped in quarantine to prevent improper release. The products had not been determined to be available for distribution, as described in 21 CFR 1271.265(c), as there was no documentation that the pre-established criteria designed to prevent communicable disease transmission had been met.\n\n7. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, your firm has not validated the manufacturing process for the adipose tissue product, Ayama™, with respect to identity, strength, quality and purity.\n\n8. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. For example,\n\na) You have not performed environmental monitoring of the aseptic processing area in association with each production run. You process batches on (b)(4) basis. However, SOP (b)(4) (Version 3, Effective date: August 8, 2020) indicates that “(b)(4) plates” sampling (i.e., contact plates and settle plates) for evaluation of viable microbial contamination of the biosafety cabinet will be performed (b)(4). Infrequent monitoring during production of the subject drug product may preclude identification of potential microbial contaminants that could adulterate your product.\n\nb) Your incubation conditions of (b)(4) plates used as contact plates and settle plates for environmental monitoring is not appropriate for the detection of viable microbial contamination. SOP (b)(4) (Version 3, Effective date: August 8, 2020) indicates that settle and contact plates should be incubated at (b)(4) for (b)(4) hours. Incubation at (b)(4) temperature for (b)(4) hours may exclude detection of certain microbial contaminants.\n\nWe acknowledge receipt of your letter dated 10\u002F25\u002F2022, which provides a response and corrective actions to FDA’s inspectional observations (FDA-483). We have reviewed the corrective actions outlined in the response. We also acknowledge your voluntary product recall of Ayama™, initiated on 09\u002F29\u002F2022, as well as your commitment to correct firm operations and\u002For procedures involving donor eligibility (including donor screening\u002Ftesting); product quarantine; equipment calibration\u002Finspection; and labeling controls. However, we have determined that the response is inadequate to address our concerns regarding the above-noted violations as indicated below.\n\n21 CFR 211.100(a) requires written procedures for the production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Process validation studies determine whether (b)(4) state of control has been established while routine monitoring of process performance attributes determines whether control is maintained. Establishment of appropriate attributes and validation of processing method(s) of your sterile, allogeneic\u002Fnon-autologous, non-family related, HCT\u002FP product, Ayama,™ to be completed, approved, and documented prior to implementation of manufacturing operations, is essential for assuring product quality over the product lifecycle.\n\nAccording to your voluntary product recall documentation, you initiated a voluntary recall based upon available information regarding your product (i.e., associated deficiencies in donor screening processes affecting three batches sourced from two donors), although you “believe that no specific concerns existed for the safety of the product”. Your response to the FDA-483 states that you believe “the corrective and preventive actions taken by [you] adequately address the inspectional observations.” Regarding your responses to observations 4 and 5 (shipping under quarantine) and observation 7 (procedures appropriate to meet core CGTP requirements), we acknowledge that you have updated your donor eligibility determination criteria and procedures. These updated documents will be reviewed and verified during the next inspection of your establishment. However, your response does not provide sufficient information as well as corrective\u002Fpreventative actions such as:\n\na) Your response lacks detail about remaining product on hand outside the recalled product and its disposition. Please identify all finished product produced, on-hand, and shipped as well as your intended disposition of this product.\n\nb) Your revised process validation report for Ayama lacks significant documentation to assure that the product has the identity, strength, purity, and quality it purports or is represented to possess. For example, it lacks donor eligibility information as well as full, proper validation (with approved protocol[s]) and approval of your processing methods (including test method suitability) for your sterile, HCT\u002FP product - Ayama™ in order to ensure your processing method:\n\n• reduces the risk of transmission of communicable disease by an HCT\u002FP (i.e., sterility); and\n\n• does not cause contamination or cross-contamination during processing; and prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of violations that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations. This letter notifies you of our findings and provides you an opportunity to address them. You should take prompt action to correct any violations and prevent their recurrence. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent via email to: Jason D. Abel, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 1, email address: orabioinspectionalcorrespondence@fda.hhs.gov (Cc: Jason.Abel@fda.hhs.gov, please include firm name and FEI # within email subject line). If you have any questions, please contact Jason D. Abel via email.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division I","Akan Biosciences, Inc.","akan-biosciences-inc-654674-04302024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fakan-biosciences-inc-654674-04302024","2026-10-26T08:07:51.818264+00:00","2024-05-21","654674","Biologics","Mukesh NMI Kumar","2026-08-20T00:04:21.225+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-04-30",{"id":77,"raw":78,"subject":37,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":87,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},1966,[79,80,81,82,37,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023\">Baxter Healthcare Corporation\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. José E. Almeida\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman, CEO and President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Baxter Healthcare Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Baxter Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Deerfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-18\u003C\u002Fp>\n\n\u003Cp>July 25, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Almeida:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm did not adequately investigate failures of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to inspect commercially distributed products (e.g., several batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Challenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles despite their lower detectability than other “dark” particles in \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber glass vials. The challenge also used a highly detectable particle range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> μm, but still indicated detection and capability issues. Similar challenges to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine were free from visible particulates.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>In your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\u003C\u002Fp>\n\n\u003Cp>However, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\u003C\u002Fp>\n\n\u003Cp>We encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\u003C\u002Fli>\n\t\u003Cli>An independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>An FDA investigator observed white spots at the bottom of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as \u003Cstrong>(b)(4)\u003C\u002Fstrong> (the product previously processed on this equipment) at levels of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> parts per million (ppm). Your limit for post-cleaning residues is not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Your response noted \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, not \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Personnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\u003C\u002Fli>\n\t\u003Cli>You lacked scientific justification for removing vials containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles from the defect kits used to qualify visual inspection processes. For example, although \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles were more difficult to reproducibly detect than \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber vials, you elected to only use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the defect kits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Equipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line).\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you commit to replacing the threaded bolt \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a \u003Cstrong>(b)(4)\u003C\u002Fstrong> conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Controls\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\u003Cbr>\n(rishikesh_jaiwant@baxter.com)\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. José E. Almeida\n\nRecipient Title\n\nChairman, CEO and President\n\nBaxter Healthcare Corporation\n\n1 Baxter Parkway\n\nDeerfield, IL 60015\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-18\n\nJuly 25, 2023\n\nDear Mr. Almeida:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\n\nYour firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\n\nIn a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\n\nYour firm did not adequately investigate failures of the (b)(4) automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the (b)(4) automatic inspection machine to inspect commercially distributed products (e.g., several batches of (b)(4) injection (b)(4) mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\n\nChallenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of (b)(4) particles despite their lower detectability than other “dark” particles in (b)(4) mL amber glass vials. The challenge also used a highly detectable particle range of (b)(4) μm, but still indicated detection and capability issues. Similar challenges to the (b)(4) automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the (b)(4) automatic inspection machine were free from visible particulates.\n\nYour response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\n\nIn your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\n\nHowever, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified (b)(4) equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\n\nWe encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\n\nIn response to this letter, provide:\n\nA written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\n\nA comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\n\nAn independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n\nA third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nAn FDA investigator observed white spots at the bottom of a (b)(4) L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as (b)(4) (the product previously processed on this equipment) at levels of up to (b)(4) parts per million (ppm). Your limit for post-cleaning residues is not more than (b)(4) ppm.\n\nYour response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and (b)(4) activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as (b)(4) ppm. Your response noted (b)(4) injection, not (b)(4) injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\n\nIn response to this letter, provide:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nYour program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\n\nPersonnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\n\nYou lacked scientific justification for removing vials containing (b)(4) particles from the defect kits used to qualify visual inspection processes. For example, although (b)(4) particles were more difficult to reproducibly detect than (b)(4) stopper particles in the (b)(4) mL amber vials, you elected to only use the (b)(4) stopper particles in the defect kits.\n\nYour response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a (b)(4).\n\nYou also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\n\nIn response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\n\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\n\nEquipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the (b)(4) filling line).\n\nYour response is inadequate. Although you commit to replacing the threaded bolt (b)(4) on the (b)(4) filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a (b)(4) conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines ((b)(4) and (b)(4)), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\n\nA comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nProcess Controls\n\nYour firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nWe request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\n\n(rishikesh_jaiwant@baxter.com)\n\n_________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Baxter Healthcare Corporation","baxter-healthcare-corporation-654136-07252023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023","2026-10-26T08:08:01.800292+00:00","2023-08-01","654136","Drugs","Mr. José E. Almeida","2026-08-20T00:49:44.234+00:00","Via Email","2023-07-25",{"id":98,"raw":99,"subject":104,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":113,"posted_date":114,"marcs_cms_no":115,"product_type":116,"closeout_date":117,"issuing_office":103,"recipient_name":118,"body_fetched_at":119,"delivery_method":120,"recipient_title":19,"reference_number":19,"action_taken_date":121,"medical_device_id":19,"response_letter_date":19},3560,[100,101,102,103,104,13,105,13],"\u003Ctime datetime=\"2021-02-02T14:20:00Z\">02\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-06T05:00:00Z\">01\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-01062021\">Entia Biosciences, Inc\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-04292021\">\u003Ctime datetime=\"2021-05-12T04:00:00Z\">05\u002F12\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Timothy A. Timmins\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Entia Biosciences, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13565 SW Tualatin Sherwood Road, Suite 800\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sherwood\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 6, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 610493\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Timmins:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the US. Food and Drug Administration (FDA) reviewed your website at the Internet address www.totalnutraceutical.com in September 2020 and December 2020, and has determined that you take orders there for the products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement. The claims on these websites establish that these products are drugs under section 201(g)(1)(8) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321 (g)(1 )(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Lion's Mane - All Natural Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product page at www.totalnutraceutical.com\u002Flions-mane-supplement contains the following claims:\u003C\u002Fp>\n\n\u003Cp>• \"Helps to lower cholesterol\"\u003Cbr>\n• \"Anti-inflammatory\"\u003Cbr>\n• \"It has been linked to having positive implications towards reducing cholesterol levels and inflammation\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Antrodia Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Antrodia Mushroom Powder at www.totalnutraceutical.com\u002Fantrodia, you claim that your product has:\u003C\u002Fp>\n\n\u003Cp>• \"Anti-inflammatory properties,\" and\u003Cbr>\n• \" ... [t]he Antrodia mushroom has long been used as a potent anti-inflammatory for a variety of conditions including liver disease, hypertension ... It is also used to help increase the body's defenses and prevent illness\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Maitake Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product page for Maitake Mushroom Powder at www.totalnutraceutical.com\u002Fmaitake states that the product:\u003C\u002Fp>\n\n\u003Cp>• \"Promotes balanced blood sugar,\" and that the mushroom has been\u003Cbr>\n• \"Found to also have cancer fighting properties\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Reishi Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Reishi Mushroom at www.totalnutraceutical.com\u002Fmushroomsreishi, you state the following:\u003C\u002Fp>\n\n\u003Cp>\"There are many reported health benefits of the Reishi mushroom. Some of these include:\u003C\u002Fp>\n\n\u003Cp>• Relief of viral infections ...\u003Cbr>\n• Prevention of heart disease\u003Cbr>\n• Reduce high blood pressure\u003Cbr>\n• Lower high cholesterol\u003Cbr>\n• Prevention of prostate cancer\u003Cbr>\n• Strong anti-inflammatory properties\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cordyceps Mushroom Powder\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page for Cordyceps Mushroom at www.totalnutraceutical.com\u002Fmushrooms-cordyceps, you state the following:\u003C\u002Fp>\n\n\u003Cp>\"There are many reported health benefits of the cordyceps mushroom. Some of these include:\u003C\u002Fp>\n\n\u003Cp>• Cholesterol reduction\u003Cbr>\n• Promotes balanced blood sugar ...\u003Cbr>\n• Faster recovery from bronchitis and respiratory diseases ...\u003Cbr>\n• Anti-tumor ...\u003Cbr>\n• ... enhanced recovery from chemotherapy\"\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cordyceps - All Natural Mushroom Dietary Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your product page at www.totalnutraceutical.com\u002Fcordyceps-supplement, you claim:\u003C\u002Fp>\n\n\u003Cp>• \"Promotes balanced blood sugar\"\u003Cbr>\n• \" ... Cordyceps has long been used to treat a variety of health conditions. Its properties range from promoting lower cholesterol to balancing blood sugar levels.\"\u003C\u002Fp>\n\n\u003Cp>Your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps -All Natural Mushroom Dietary Supplement products are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are \"new drugs\" under section 201 (p) of the Act [21 U.S.C. § 321 (p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301 (d) and 505(a) of the Act [21 U.S.C. §§ 331 (d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003Cbr>\n\u003Cbr>\nYour products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301 (a) of the Act [21 U.S.C. § 331 (a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen ( 15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be sent to the Food and Drug Administration, Attention: Mark Babbitt, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions, please contact Mark Babbitt at \u003Cspan>509-353-2136\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> ext. 107.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nMiriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Mail\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTimothy A. Timmins\n\nRecipient Title\n\nPresident\n\nEntia Biosciences, Inc\n\n13565 SW Tualatin Sherwood Road, Suite 800\n\nSherwood, OR 97140\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nJanuary 6, 2021\n\nIn reply, refer to CMS 610493\n\nWARNING LETTER\n\nDear Mr. Timmins:\n\nThis is to advise you that the US. Food and Drug Administration (FDA) reviewed your website at the Internet address www.totalnutraceutical.com in September 2020 and December 2020, and has determined that you take orders there for the products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement. The claims on these websites establish that these products are drugs under section 201(g)(1)(8) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321 (g)(1 )(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nLion's Mane - All Natural Supplement\n\nYour product page at www.totalnutraceutical.com\u002Flions-mane-supplement contains the following claims:\n\n• \"Helps to lower cholesterol\"\n\n• \"Anti-inflammatory\"\n\n• \"It has been linked to having positive implications towards reducing cholesterol levels and inflammation\"\n\nAntrodia Mushroom Powder\n\nOn your product page for Antrodia Mushroom Powder at www.totalnutraceutical.com\u002Fantrodia, you claim that your product has:\n\n• \"Anti-inflammatory properties,\" and\n\n• \" ... [t]he Antrodia mushroom has long been used as a potent anti-inflammatory for a variety of conditions including liver disease, hypertension ... It is also used to help increase the body's defenses and prevent illness\"\n\nMaitake Mushroom Powder\n\nYour product page for Maitake Mushroom Powder at www.totalnutraceutical.com\u002Fmaitake states that the product:\n\n• \"Promotes balanced blood sugar,\" and that the mushroom has been\n\n• \"Found to also have cancer fighting properties\"\n\nReishi Mushroom Powder\n\nOn your product page for Reishi Mushroom at www.totalnutraceutical.com\u002Fmushroomsreishi, you state the following:\n\n\"There are many reported health benefits of the Reishi mushroom. Some of these include:\n\n• Relief of viral infections ...\n\n• Prevention of heart disease\n\n• Reduce high blood pressure\n\n• Lower high cholesterol\n\n• Prevention of prostate cancer\n\n• Strong anti-inflammatory properties\"\n\nCordyceps Mushroom Powder\n\nOn your product page for Cordyceps Mushroom at www.totalnutraceutical.com\u002Fmushrooms-cordyceps, you state the following:\n\n\"There are many reported health benefits of the cordyceps mushroom. Some of these include:\n\n• Cholesterol reduction\n\n• Promotes balanced blood sugar ...\n\n• Faster recovery from bronchitis and respiratory diseases ...\n\n• Anti-tumor ...\n\n• ... enhanced recovery from chemotherapy\"\n\nCordyceps - All Natural Mushroom Dietary Supplement\n\nOn your product page at www.totalnutraceutical.com\u002Fcordyceps-supplement, you claim:\n\n• \"Promotes balanced blood sugar\"\n\n• \" ... Cordyceps has long been used to treat a variety of health conditions. Its properties range from promoting lower cholesterol to balancing blood sugar levels.\"\n\nYour Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps -All Natural Mushroom Dietary Supplement products are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are \"new drugs\" under section 201 (p) of the Act [21 U.S.C. § 321 (p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301 (d) and 505(a) of the Act [21 U.S.C. §§ 331 (d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). \"Adequate directions for use\" means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Lion's Mane -All Natural Supplement, Antrodia Mushroom Powder, Maitake Mushroom Powder, Reishi Mushroom Powder, Cordyceps Mushroom Powder, and Cordyceps - All Natural Mushroom Dietary Supplement products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301 (a) of the Act [21 U.S.C. § 331 (a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\n\nWithin fifteen ( 15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour written reply should be sent to the Food and Drug Administration, Attention: Mark Babbitt, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions, please contact Mark Babbitt at 509-353-2136 ext. 107.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","Entia Biosciences, Inc","entia-biosciences-inc-610493-01062021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fentia-biosciences-inc-610493-01062021","2026-10-26T08:08:35.712624+00:00","Closed Out","2021-02-02","610493","Dietary SupplementsFood & Beverages","2021-05-12","Timothy A. Timmins","2026-08-20T03:25:06.576+00:00","Overnight Mail","2021-01-06",{"id":123,"raw":124,"subject":37,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":66,"fei_number":19,"letter_url":133,"updated_at":134,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":136,"product_type":92,"closeout_date":19,"issuing_office":36,"recipient_name":137,"body_fetched_at":138,"delivery_method":95,"recipient_title":19,"reference_number":139,"action_taken_date":140,"medical_device_id":19,"response_letter_date":19},1223,[125,126,127,36,128,13,13,13],"\u003Ctime datetime=\"2024-10-08T13:20:00Z\">10\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-24T04:00:00Z\">09\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024\">MMC Healthcare Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-62\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nageswara Rao Gupta Manepalli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MMC Healthcare Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-B Sidco Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thirumazhisai, Chennai\u003C\u002Fspan> \u003Cspan>600124\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ceo@mmchealthcareltd.com\"> ceo@mmchealthcareltd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-62\u003C\u002Fp>\n\n\u003Cp>September 24, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Manepalli:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 18, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection of your facility our Investigator observed that your 2021 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research &amp; Development Manager, and Production Manager admitted to participating in these practices.\u003C\u002Fp>\n\n\u003Cp>Review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Capsules \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\u003C\u002Fp>\n\n\u003Cp>Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>Also describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it does not provide sufficient details describing:\u003C\u002Fp>\n\n\u003Cp>• Timeframe for your corrective action.\u003Cbr>\n• Security features of your updated UV-Vis computer system.\u003Cbr>\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\u003Cbr>\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\u003Cbr>\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\u003C\u002Fp>\n\n\u003Cp>It is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; o An evaluation of the impact of this violation.\u003Cbr>\n&nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\u003Cbr>\n&nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; o A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; o System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; o Timeline for the implementation and qualification of your updated UV-Vis software.\u003Cbr>\n&nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; o Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>\n&nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; o Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; o Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your \u003Cem>E. coli\u003C\u002Fem> test method for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\u003C\u002Fp>\n\n\u003Cp>Test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution within expiry using the revised method, all of which passed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>\n&nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; o A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003Cbr>\n&nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 6, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-24-62\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nageswara Rao Gupta Manepalli\n\nRecipient Title\n\nManaging Director\u002FCEO\n\nMMC Healthcare Ltd.\n\n34-B Sidco Industrial Estate\n\nThirumazhisai, Chennai 600124\n\nTamil Nadu\n\nIndia\n\nceo@mmchealthcareltd.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-62\n\nSeptember 24, 2024\n\nDear Mr. Manepalli:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 18, 2024 response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nDuring the inspection of your facility our Investigator observed that your 2021 (b)(4) Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research & Development Manager, and Production Manager admitted to participating in these practices.\n\nReview of the (b)(4) Capsules (b)(4) mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\n\nIn your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\n\nYour response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\n\nData integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\n\nIn your response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAlso describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\n\nIn your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\n\nYour response is inadequate because it does not provide sufficient details describing:\n\n• Timeframe for your corrective action.\n\n• Security features of your updated UV-Vis computer system.\n\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\n\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\n\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\n\nIt is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\n\no An evaluation of the impact of this violation.\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Timeline for the implementation and qualification of your updated UV-Vis software.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\n\no A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\n\no Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\n\n3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your E. coli test method for (b)(4) Solution and (b)(4) Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\n\nTest methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\n\nIn your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of (b)(4) Solution within expiry using the revised method, all of which passed.\n\nYour response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 6, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nArticles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","MMC Healthcare Ltd.","mmc-healthcare-ltd-684644-09242024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024","2026-10-26T08:09:26.775337+00:00","2024-10-08","684644","Mr. Nageswara Rao Gupta Manepalli","2026-08-19T22:31:41.964+00:00","320-24-62","2024-09-24",{"id":142,"raw":143,"subject":104,"body_html":149,"body_text":150,"firm_name":151,"letter_id":152,"created_at":153,"fei_number":19,"letter_url":154,"updated_at":155,"action_type":22,"case_status":113,"posted_date":156,"marcs_cms_no":157,"product_type":158,"closeout_date":159,"issuing_office":147,"recipient_name":160,"body_fetched_at":161,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":162,"medical_device_id":19,"response_letter_date":19},2340,[144,145,146,147,104,13,148,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022\">Calroy Health Sciences, LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-07192023\">\u003Ctime datetime=\"2023-07-21T04:00:00Z\">07\u002F21\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chen and Mr. Hoyt\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Calroy Health Sciences, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14362 N Frank Lloyd Wright, Suite 1000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636311\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chen and Mr. Hoyt:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Arterosil product page at www.arterosil.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Under the “Patient Education” Tab\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; &nbsp;and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chen and Mr. Hoyt\n\nCalroy Health Sciences, LLC\n\n14362 N Frank Lloyd Wright, Suite 1000\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636311\n\nDear Mr. Chen and Mr. Hoyt:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\n\nOn your Arterosil product page at www.arterosil.com:\n\n\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\n\n“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\n\n\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\n\nUnder the “Patient Education” Tab\n\n\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\n\n\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\n\n\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\n\n\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\n\n\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\n\nYour Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","Calroy Health Sciences, LLC","calroy-health-sciences-llc-636311-11142022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022","2026-10-26T08:08:10.528128+00:00","2022-11-17","636311","Dietary SupplementsDrugs","2023-07-21","Mr. Chen and Mr. Hoyt","2026-08-20T01:25:36.732+00:00","2022-11-14",{"id":164,"raw":165,"subject":104,"body_html":172,"body_text":173,"firm_name":174,"letter_id":175,"created_at":176,"fei_number":19,"letter_url":177,"updated_at":178,"action_type":22,"case_status":113,"posted_date":179,"marcs_cms_no":180,"product_type":181,"closeout_date":182,"issuing_office":169,"recipient_name":183,"body_fetched_at":184,"delivery_method":185,"recipient_title":19,"reference_number":19,"action_taken_date":186,"medical_device_id":19,"response_letter_date":19},3011,[166,167,168,169,170,13,171,13],"\u003Ctime datetime=\"2021-11-30T14:20:00Z\">11\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-18T05:00:00Z\">11\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-11182021\">Saffron Health Sciences\u003C\u002Fa>","Division of Human and Animal Food Operations East II","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-01182022\">\u003Ctime datetime=\"2022-02-15T05:00:00Z\">02\u002F15\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Song Gao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Saffron Health Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13 Dexter Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>E Brunswick\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08816-2873\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #615429\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 18, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Gao;\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fsaffronhealthsci.com in November 2021 and determined that you take orders there for the products Crocin Rich, Crocin Rich II, and Crocin Rich Plus. We have also reviewed your social media website www.facebook.com\u002Fsaffronhealthsci\u002F, which directs customers to https:\u002F\u002Fsaffronhealthsci.com to purchase your products, and your firm’s store at www.amazon.com. The claims on these websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, including COVID-19 in people\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violated the Act. You may find the Act and FDA regulations through links on FDA’s homepage at&nbsp;\u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On your website homepage (https:\u002F\u002Fsaffronhealthsci.com):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Supplements for Healthy Aging and Quality of Life: A natural multi-target approach for Alzheimer’s and age-related diseases”\u003C\u002Fli>\n\t\u003Cli>“Crocin supplements are designed for … Alzheimer’s … Macular degeneration (AMD), diabetic maculopathy”\u003C\u002Fli>\n\t\u003Cli>“[W]e identified crocin, the most important active constituent of saffron, as the best natural … anti-inflammatory agent .…”\u003C\u002Fli>\n\t\u003Cli>“Dozens of clinical and hundreds of preclinical studies in recent years revealed crocin\u002Fsaffron having significant effects to improve conditions in patients with Alzheimer’s, mild cognitive impairments, vascular dementia, age-related macular degenerative (AMD), stroke, depression, multiple sclerosis, and a few other diseases.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Can Crocin Protect as an Antioxidant and Anti-inflammatory Agent Against Coronavirus (COVID-19)? A combination of the ancient wisdom of natural healing with current research.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fis-crocin-the-active-constituent-of-saffron-crocus-sativus-a-potential-antioxidant-and-anti-inflammation-agent-against-coronavirus-covid-19-a-combination-of-ancient-wisdom-in-natural-healing-with-current-research):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin, the unique water-soluble carotenoid with potent … anti-inflammation effects, could be a promising natural agent to boost immune system and body defense against COVID-19.”\u003C\u002Fli>\n\t\u003Cli>“Published study results have revealed multi-target effects of crocin in modulating … inflammatory cytokines ….”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on lungs: Lungs are initially believed to be the main organ affected by COVID-19. Crocin was recently reported to attenuate lung inflammation, pulmonary vascular dysfunction and associated pulmonary fibrosis, as well as alleviate acute respiratory distress syndrome in animal studies ….”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on clotting: Crocin has been reported in series of recent studies to suppress plasminogen activator inhibitor-1 (PAI-1) activity to ameliorate thrombosis …, inhibit atheromatous plaque formation … and inhibits [sic] platelet aggregation …. These findings indicate effects of crocin could potentially prevent and reduce the impacts of COVID-19.”\u003C\u002Fli>\n\t\u003Cli>“Protective effects of crocin on the heart: … Crocin attenuates … inflammation, arrhythmias, injuries, and hemodynamic parameters from myocardial infraction and ischemic-reperfusion … [C]rocin is also revealed to attenuate myocardial fibrosis ….”\u003C\u002Fli>\n\t\u003Cli>“A recent systemic review of meta-analysis of clinical evidence of saffron and crocin on cardiovascular risk factors has looked into 11 randomized clinical trials … Among these 11 trials of saffron and crocin, 6 evaluated effects of crocin (15-100mg\u002Fday) and demonstrate its significant effects on patients with Schizophrenia, diabetic macular edema, metabolic syndrome …, and coronary artery disease ….”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Crocin as a Neuroprotective Agent Against Stroke.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-as-a-natural-neuroprotective-agent-forstroke):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The neuroprotective effects of crocin against stroke is the focus of this article.”\u003C\u002Fli>\n\t\u003Cli>“A number of studies have demonstrated that crocin provides neuroprotective … anti-inflammatory, edema suppressive, and brain injury protective effects ….”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin as a natural neuroprotective agent could help reduce risk of stroke and improve recovery.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Human Study Indicates Crocin Benefits Multiple Sclerosis Patients.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhuman-study-indicates-crocin-benefits-multiple-sclerosis-patients):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“A 4-week double-blind, randomized, and placebo-controlled trial of crocin in multiple sclerosis patients … [resulted in the following] [h]ightlights of the study.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha (TNF\u003Cspan>\u003Cspan>a\u003C\u002Fspan>\u003C\u002Fspan>), and interleukin 17 (IL-17) … in the serum of patients treated with crocin (30mg\u002Fday) compared with the placebo group.”\u003Cbr>\n&nbsp; &nbsp; o “Treatment of crocin in MS patients provided protection against oxidative and inflammation damage biomarkers during the disease process.”\u003Cbr>\n&nbsp; &nbsp; o “The results suggest crocin as a promising therapeutic agent in prevention of progressive injury during MS.”\u003C\u002Fp>\n\n\u003Cp>From the blog section of your webpage titled “Crocin Improves Sleep Quality and Removes Amyloid, Quality Sleep Washes Out Alzheimer’s Toxins and Amyloid.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneralknowledge\u002Fquality-sleep-washes-out-alzheimer-s-toxins-and-amyloid-natural-crocin-improves-sleepquality-and-removes-amyloid):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[C]rocin was found significantly improved… depression, anxiety, … in patients … who were under Methadone maintenance treatment.”\u003C\u002Fli>\n\t\u003Cli>“Crocin was found to prevent generation of toxic amyloid peptides through inhibiting two key enzymes in Alzheimer Disease Neuronal Cell Culture Models ….”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin has been shown in at least 20 animal studies to improve memory deficits induced by amyloid and other drugs or toxins … Therefore, Crocin is considered as an effective option … against Alzheimer’s.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “Crocin and Saffron Are Good for Age-Related Eye Diseases.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-saffron-is-good-for-age-related-eye-diseases):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Clinical studies of saffron and its main active constituent crocin in recent years suggested that supplementation with crocin or saffron may have positive effects on various vision-related parameters in adults with age-related macular degeneration (AMD), glaucoma, diabetic maculopathy, and Stargardt macular dystrophy.”\u003C\u002Fli>\n\t\u003Cli>“Crocin (15 mg\u002Fday) significantly decreased central macula thickness and improved best corrected visual acuity (BCVA) or eyesight, in patients with diabetic macular edema after three months treatment. The crocin treatment also resulted in significant improvements in levels of fasting blood glucose and glycated haemoglobin A1c.”\u003C\u002Fli>\n\t\u003Cli>“[C]rocin and saffron were also found to have inhibitory effects on cataract ....”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the blog section of your webpage titled “How can Saffron and Crocin Help Depression?” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhow-can-saffron-and-crocin-help-depression):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[S]everal preclinical studies have confirmed the antidepressant effects of crocin. Crocin was also demonstrated in animal studies to improve anxiety and obsessive-compulsive disorder and reduce stress-induced anorexia ....”\u003C\u002Fli>\n\t\u003Cli>“Human studies in recent years further indicated that the antidepressant-like properties of saffron are primarily due to crocin. In a 4-week study, crocin (30mg\u002Fday) effects on depression were compared with a serotonin reuptake inhibitor drug (fluoxetine, sertraline, and citalopram) in a randomized, double-blind, placebo-controlled, pilot clinical trial. Results of this human study showed crocin significantly improved scores on BDI, BAI, and GHQ compared to the placebo group. The authors concluded crocin could be administered as an adjunctive treatment in major depressive disorder patients.”\u003C\u002Fli>\n\t\u003Cli>“Yet in another 8-week randomized double-blind controlled clinical study, saffron aqueous extract (30mg\u002Fday) and crocin (30mg\u002Fday) was compared against placebo on health-related quality of life, depression, and sexual desire in coronary artery disease patients. Both saffron and crocin significantly improved depression and quality of life in these patients with CAD ....”\u003C\u002Fli>\n\t\u003Cli>“Crocin also significantly improved International Index of Erectile Functions ....”\u003C\u002Fli>\n\t\u003Cli>“[C]urcumin [an ingredient in the Crocin Rich Plus product] was reported to have the potential to ameliorate depressive symptoms”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your product webpage for Crocin Rich II (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-ii):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CROCIN RICH II Is Good For … Help recovery of nerve and traumatic injury”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your product webpage for Crocin Rich Plus (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-plus):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CROCIN RICH plus Is Good For … Help recovery of nerve and traumatic injury”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the section of your webpage titled “Crocin &amp; Saffron News” (https:\u002F\u002Fsaffronhealthsci.com\u002Fpages\u002Fsaffron-reseach-news):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin is … a potent … anti-inflammatory agent.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-Carotenoid-Combination-Zeaxanthin\u002Fdp\u002FB01EDCRVKC):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Ten (10) recent clinical studies reported crocin\u002Fsaffron supplementation support visual acuity and eye functions in patients with AMD, diabetic retinopathy, and glaucoma.”\u003C\u002Fli>\n\t\u003Cli>“Clinical findings indicate crocin\u002Fsaffron supplementation is superior and provide markable eye health benefits in comparative studies to AREDS 2 formula.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich II (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-II-Carotenoid-Strength\u002Fdp\u002FB01EDCRW4W\u002Fref=sr_1_2?dchild=1&amp;m=A20ZTQB2YT4EN8&amp;marketplaceID=ATVPDKIKX0DER&amp;qid=1628895170&amp;s=merchant-items&amp;sr=1-2):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Rich II is good for: … Help recovery of nerve and traumatic injury … Reduce hangovers”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your Amazon product sales page for Crocin Rich Plus (https:\u002F\u002Fwww.amazon.com\u002FProvides-Concentrated-Equivalent-Saffron-Antioxidants\u002Fdp\u002FB01EDCRWU6\u002Fref=sr_1_1?dchild=1&amp;m=A20ZTQB2YT4EN8&amp;marketplaceID=ATVPDKIKX0DER&amp;qid=1628895736&amp;s=merchant-items&amp;sr=1-1):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Crocin Rich plus is good for: … Help recovery of nerve and traumatic injury … Reduce Hangovers”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Examples of claims observed on your social media page at https:\u002F\u002Fwww.facebook.com\u002Fsaffronhealthsci\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Posted December 1, 2020: “Don't miss knowing the recent clinical findings of Crocin … on visual acuity and eye functions in patients with AMD, glaucoma, diabetic maculopathy, etc. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fcrocin-and-eye-health”\u003C\u002Fli>\n\t\u003Cli>Posted September 27, 2020: “A natural approach with multi-target, neuroprotective, memory and cognition improving effects could offer a safe and effective alternative for Alzheimer’s disease. … https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fa-natural-composition...” Below this is a picture of the Crocin Rich Plus product with the caption “A Natural Composition with Multi-Target Neuroprotective Effects for Alzheimer’s.”\u003C\u002Fli>\n\t\u003Cli>Posted June 23, 2020: “Without a vaccine and cure available for coronavirus (COVID-19), an alternative for the prevention and mitigation of the impact of COVID-19 could come from unique natural products with multi-target and immune system boosting effects. A combination of ancient wisdom of natural remedies with the latest scientific research may offer a promising approach to battle COVID-19 effectively. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fis-crocin-the-active...” Below this is an image of a coronavirus with the caption “Can Crocin Protect as an …Anti-inflammatory Agent Against Coronavirus…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Crocin Rich, Crocin Rich II and Crocin Rich Plus are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under Section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]. FDA approves new drugs on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in Section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Crocin Rich, Crocin Rich II, and Crocin Rich Plus are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Crocin Rich, Crocin Rich II, and Crocin Rich Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates Section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, Maryland 21117. If you should have any questions regarding any issue in this letter, please contact Andrew J. Howard, Compliance Officer, at (410) 779-5125 or by email Andrew.Howard@fda.hhs.gov. Files greater than 100 megabytes may be submitted as smaller files in separate emails.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Randy F. Pack\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision Director\u003Cbr>\nHuman &amp; Animal Food Division II East\u003Cbr>\nBaltimore District Office\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Song Gao\n\nSaffron Health Sciences\n\n13 Dexter Rd\n\nE Brunswick, NJ 08816-2873\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nWARNING LETTER\n\nCMS #615429\n\nNovember 18, 2021\n\nDear Dr. Gao;\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fsaffronhealthsci.com in November 2021 and determined that you take orders there for the products Crocin Rich, Crocin Rich II, and Crocin Rich Plus. We have also reviewed your social media website www.facebook.com\u002Fsaffronhealthsci\u002F, which directs customers to https:\u002F\u002Fsaffronhealthsci.com to purchase your products, and your firm’s store at www.amazon.com. The claims on these websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease, including COVID-19 in people1. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violated the Act. You may find the Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn your website homepage (https:\u002F\u002Fsaffronhealthsci.com):\n\n“Crocin Supplements for Healthy Aging and Quality of Life: A natural multi-target approach for Alzheimer’s and age-related diseases”\n\n“Crocin supplements are designed for … Alzheimer’s … Macular degeneration (AMD), diabetic maculopathy”\n\n“[W]e identified crocin, the most important active constituent of saffron, as the best natural … anti-inflammatory agent .…”\n\n“Dozens of clinical and hundreds of preclinical studies in recent years revealed crocin\u002Fsaffron having significant effects to improve conditions in patients with Alzheimer’s, mild cognitive impairments, vascular dementia, age-related macular degenerative (AMD), stroke, depression, multiple sclerosis, and a few other diseases.”\n\nFrom the blog section of your webpage titled “Can Crocin Protect as an Antioxidant and Anti-inflammatory Agent Against Coronavirus (COVID-19)? A combination of the ancient wisdom of natural healing with current research.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fis-crocin-the-active-constituent-of-saffron-crocus-sativus-a-potential-antioxidant-and-anti-inflammation-agent-against-coronavirus-covid-19-a-combination-of-ancient-wisdom-in-natural-healing-with-current-research):\n\n“Crocin, the unique water-soluble carotenoid with potent … anti-inflammation effects, could be a promising natural agent to boost immune system and body defense against COVID-19.”\n\n“Published study results have revealed multi-target effects of crocin in modulating … inflammatory cytokines ….”\n\n“Protective effects of crocin on lungs: Lungs are initially believed to be the main organ affected by COVID-19. Crocin was recently reported to attenuate lung inflammation, pulmonary vascular dysfunction and associated pulmonary fibrosis, as well as alleviate acute respiratory distress syndrome in animal studies ….”\n\n“Protective effects of crocin on clotting: Crocin has been reported in series of recent studies to suppress plasminogen activator inhibitor-1 (PAI-1) activity to ameliorate thrombosis …, inhibit atheromatous plaque formation … and inhibits [sic] platelet aggregation …. These findings indicate effects of crocin could potentially prevent and reduce the impacts of COVID-19.”\n\n“Protective effects of crocin on the heart: … Crocin attenuates … inflammation, arrhythmias, injuries, and hemodynamic parameters from myocardial infraction and ischemic-reperfusion … [C]rocin is also revealed to attenuate myocardial fibrosis ….”\n\n“A recent systemic review of meta-analysis of clinical evidence of saffron and crocin on cardiovascular risk factors has looked into 11 randomized clinical trials … Among these 11 trials of saffron and crocin, 6 evaluated effects of crocin (15-100mg\u002Fday) and demonstrate its significant effects on patients with Schizophrenia, diabetic macular edema, metabolic syndrome …, and coronary artery disease ….”\n\nFrom the blog section of your webpage titled “Crocin as a Neuroprotective Agent Against Stroke.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-as-a-natural-neuroprotective-agent-forstroke):\n\n“The neuroprotective effects of crocin against stroke is the focus of this article.”\n\n“A number of studies have demonstrated that crocin provides neuroprotective … anti-inflammatory, edema suppressive, and brain injury protective effects ….”\n\n“[C]rocin as a natural neuroprotective agent could help reduce risk of stroke and improve recovery.”\n\nFrom the blog section of your webpage titled “Human Study Indicates Crocin Benefits Multiple Sclerosis Patients.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhuman-study-indicates-crocin-benefits-multiple-sclerosis-patients):\n\n“A 4-week double-blind, randomized, and placebo-controlled trial of crocin in multiple sclerosis patients … [resulted in the following] [h]ightlights of the study.”\n\no “Findings revealed a significant decrease in the level of important pathogenic factors in MS, including lipid peroxidation, DNA damage, tumor necrosis factor-alpha (TNFa), and interleukin 17 (IL-17) … in the serum of patients treated with crocin (30mg\u002Fday) compared with the placebo group.”\n\no “Treatment of crocin in MS patients provided protection against oxidative and inflammation damage biomarkers during the disease process.”\n\no “The results suggest crocin as a promising therapeutic agent in prevention of progressive injury during MS.”\n\nFrom the blog section of your webpage titled “Crocin Improves Sleep Quality and Removes Amyloid, Quality Sleep Washes Out Alzheimer’s Toxins and Amyloid.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneralknowledge\u002Fquality-sleep-washes-out-alzheimer-s-toxins-and-amyloid-natural-crocin-improves-sleepquality-and-removes-amyloid):\n\n“[C]rocin was found significantly improved… depression, anxiety, … in patients … who were under Methadone maintenance treatment.”\n\n“Crocin was found to prevent generation of toxic amyloid peptides through inhibiting two key enzymes in Alzheimer Disease Neuronal Cell Culture Models ….”\n\n“[C]rocin has been shown in at least 20 animal studies to improve memory deficits induced by amyloid and other drugs or toxins … Therefore, Crocin is considered as an effective option … against Alzheimer’s.”\n\nFrom the blog section of your webpage titled “Crocin and Saffron Are Good for Age-Related Eye Diseases.” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fcrocin-saffron-is-good-for-age-related-eye-diseases):\n\n“Clinical studies of saffron and its main active constituent crocin in recent years suggested that supplementation with crocin or saffron may have positive effects on various vision-related parameters in adults with age-related macular degeneration (AMD), glaucoma, diabetic maculopathy, and Stargardt macular dystrophy.”\n\n“Crocin (15 mg\u002Fday) significantly decreased central macula thickness and improved best corrected visual acuity (BCVA) or eyesight, in patients with diabetic macular edema after three months treatment. The crocin treatment also resulted in significant improvements in levels of fasting blood glucose and glycated haemoglobin A1c.”\n\n“[C]rocin and saffron were also found to have inhibitory effects on cataract ....”\n\nFrom the blog section of your webpage titled “How can Saffron and Crocin Help Depression?” (https:\u002F\u002Fsaffronhealthsci.com\u002Fblogs\u002Fgeneral-knowledge\u002Fhow-can-saffron-and-crocin-help-depression):\n\n“[S]everal preclinical studies have confirmed the antidepressant effects of crocin. Crocin was also demonstrated in animal studies to improve anxiety and obsessive-compulsive disorder and reduce stress-induced anorexia ....”\n\n“Human studies in recent years further indicated that the antidepressant-like properties of saffron are primarily due to crocin. In a 4-week study, crocin (30mg\u002Fday) effects on depression were compared with a serotonin reuptake inhibitor drug (fluoxetine, sertraline, and citalopram) in a randomized, double-blind, placebo-controlled, pilot clinical trial. Results of this human study showed crocin significantly improved scores on BDI, BAI, and GHQ compared to the placebo group. The authors concluded crocin could be administered as an adjunctive treatment in major depressive disorder patients.”\n\n“Yet in another 8-week randomized double-blind controlled clinical study, saffron aqueous extract (30mg\u002Fday) and crocin (30mg\u002Fday) was compared against placebo on health-related quality of life, depression, and sexual desire in coronary artery disease patients. Both saffron and crocin significantly improved depression and quality of life in these patients with CAD ....”\n\n“Crocin also significantly improved International Index of Erectile Functions ....”\n\n“[C]urcumin [an ingredient in the Crocin Rich Plus product] was reported to have the potential to ameliorate depressive symptoms”\n\nOn your product webpage for Crocin Rich II (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-ii):\n\n“CROCIN RICH II Is Good For … Help recovery of nerve and traumatic injury”\n\nOn your product webpage for Crocin Rich Plus (https:\u002F\u002Fsaffronhealthsci.com\u002Fproducts\u002Fcrocin-rich-plus):\n\n“CROCIN RICH plus Is Good For … Help recovery of nerve and traumatic injury”\n\nFrom the section of your webpage titled “Crocin & Saffron News” (https:\u002F\u002Fsaffronhealthsci.com\u002Fpages\u002Fsaffron-reseach-news):\n\n“Crocin is … a potent … anti-inflammatory agent.”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-Carotenoid-Combination-Zeaxanthin\u002Fdp\u002FB01EDCRVKC):\n\n“Ten (10) recent clinical studies reported crocin\u002Fsaffron supplementation support visual acuity and eye functions in patients with AMD, diabetic retinopathy, and glaucoma.”\n\n“Clinical findings indicate crocin\u002Fsaffron supplementation is superior and provide markable eye health benefits in comparative studies to AREDS 2 formula.”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich II (https:\u002F\u002Fwww.amazon.com\u002FCrocin-Rich-II-Carotenoid-Strength\u002Fdp\u002FB01EDCRW4W\u002Fref=sr_1_2?dchild=1&m=A20ZTQB2YT4EN8&marketplaceID=ATVPDKIKX0DER&qid=1628895170&s=merchant-items&sr=1-2):\n\n“Crocin Rich II is good for: … Help recovery of nerve and traumatic injury … Reduce hangovers”\n\nExamples of claims observed on your Amazon product sales page for Crocin Rich Plus (https:\u002F\u002Fwww.amazon.com\u002FProvides-Concentrated-Equivalent-Saffron-Antioxidants\u002Fdp\u002FB01EDCRWU6\u002Fref=sr_1_1?dchild=1&m=A20ZTQB2YT4EN8&marketplaceID=ATVPDKIKX0DER&qid=1628895736&s=merchant-items&sr=1-1):\n\n“Crocin Rich plus is good for: … Help recovery of nerve and traumatic injury … Reduce Hangovers”\n\nExamples of claims observed on your social media page at https:\u002F\u002Fwww.facebook.com\u002Fsaffronhealthsci\u002F:\n\nPosted December 1, 2020: “Don't miss knowing the recent clinical findings of Crocin … on visual acuity and eye functions in patients with AMD, glaucoma, diabetic maculopathy, etc. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fcrocin-and-eye-health”\n\nPosted September 27, 2020: “A natural approach with multi-target, neuroprotective, memory and cognition improving effects could offer a safe and effective alternative for Alzheimer’s disease. … https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fa-natural-composition...” Below this is a picture of the Crocin Rich Plus product with the caption “A Natural Composition with Multi-Target Neuroprotective Effects for Alzheimer’s.”\n\nPosted June 23, 2020: “Without a vaccine and cure available for coronavirus (COVID-19), an alternative for the prevention and mitigation of the impact of COVID-19 could come from unique natural products with multi-target and immune system boosting effects. A combination of ancient wisdom of natural remedies with the latest scientific research may offer a promising approach to battle COVID-19 effectively. https:\u002F\u002Fsaffronhealthsci.com\u002F...\u002Fis-crocin-the-active...” Below this is an image of a coronavirus with the caption “Can Crocin Protect as an …Anti-inflammatory Agent Against Coronavirus…”\n\nYour Crocin Rich, Crocin Rich II and Crocin Rich Plus are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under Section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in Sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), 355(a)]. FDA approves new drugs on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in Section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Crocin Rich, Crocin Rich II, and Crocin Rich Plus are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Crocin Rich, Crocin Rich II, and Crocin Rich Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates Section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, Maryland 21117. If you should have any questions regarding any issue in this letter, please contact Andrew J. Howard, Compliance Officer, at (410) 779-5125 or by email Andrew.Howard@fda.hhs.gov. Files greater than 100 megabytes may be submitted as smaller files in separate emails.\n\nSincerely,\n\n\u002FS\u002F\n\nRandy F. Pack\n\nProgram Division Director\n\nDivision Director\n\nHuman & Animal Food Division II East\n\nBaltimore District Office\n\n___________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.","Saffron Health Sciences","saffron-health-sciences-615429-11182021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-health-sciences-615429-11182021","2026-10-26T08:09:52.649006+00:00","2021-11-30","615429","DrugsFood & Beverages","2022-02-15","Dr. Song Gao","2026-08-20T02:23:11.401+00:00","VIA UPS","2021-11-18",{"id":188,"raw":189,"subject":194,"body_html":195,"body_text":196,"firm_name":197,"letter_id":198,"created_at":42,"fei_number":19,"letter_url":199,"updated_at":200,"action_type":22,"case_status":23,"posted_date":201,"marcs_cms_no":202,"product_type":92,"closeout_date":19,"issuing_office":193,"recipient_name":203,"body_fetched_at":204,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":205,"medical_device_id":19,"response_letter_date":19},22,[190,191,192,193,194,13,13,13],"\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-05T04:00:00Z\">06\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmineral-biosciences-llc-724745-06052026\">Mineral BioSciences, LLC \u003C\u002Fa>","Human Foods Program","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luke C. Blotsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mineral BioSciences, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4050 S Sarival Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Goodyear\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85338-3233\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 5, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #724745\u003C\u002Fp>\u003Cp>Dear Mr. Blotsky:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4050 S Sarival Ave, Goodyear, AZ, on November 12-24, 2025. Based on inspectional findings and subsequent review of your websites https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F, and your Facebook and Instagram social media pages at https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F and https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on November 24, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated December 18, 2025, April 13, 2026, April 30, 2026, and May 1, 2026, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your websites at the Internet addresses https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F in May 2026 and determined that you take orders on the website https:\u002F\u002Fprotectcells.com\u002F for your products Totala Fulvic Ionic Mineral Complex and Ionicell. We also reviewed your social media pages on Facebook (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F) and Instagram (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F) in March 2026, where you direct consumers to your website, https:\u002F\u002Fprotectcells.com\u002F, to purchase your products. Claims on your social media webpages establish that your Totala Fulvic Ionic Mineral Complex and Ionicell products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex AND Ionicell\u003C\u002Fu>\u003Cbr>“Did you know Higher A1C levels are linked to diabetes complications? But did you also know that case reports have shown that Ioniplex can help control post-prandial blood sugar levels?” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated February 24, 2022)\u003C\u002Fli>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex AND Ionicell\u003C\u002Fu>\u003Cbr>“Ioniplex has been clinically shown to repair and stimulate the body at the cellular level, leading to better glucose management.” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated January 29, 2021)\u003C\u002Fli>\u003Cli>\u003Cu>Totala Fulvic Ionic Mineral Complex\u003C\u002Fu>\u003Cbr>“[H]as been taking Totala … and has noticed not only a drop in his blood pressure, but less pain in his joints…” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 23, 2018)\u003C\u002Fli>\u003Cli>\u003Cu>Ionicell\u003C\u002Fu>\u003Cbr>“[H]as been taking IoniCell for several weeks and has already noticed a drop in her daily glucose levels and fasting glucose levels.” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 6, 2018)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your products Totala Fulvic Ionic Mineral Complex and Ionicell are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Totala Fulvic Ionic Mineral Complex and Ionicell fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility on November 12-24, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell products are also adulterated dietary supplements under section 402(g)(1) of the Act.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to meet sanitation requirements that apply to your physical plant and grounds under 21 CFR 111.15. Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>You failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). For example, from November 12-13, 2025, our investigator observed insulation hanging from the ceiling, one light casing which appeared to be taped with water leaking from it, two holes in your wall exposing outside elements, and multiple doors, including bay doors, with opening gaps allowing light to shine into your facility.\u003C\u002Fli>\u003Cli>You failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). For example, on November 13, 2025, our investigator reviewed your pest control records for April 2025 through November 2025 and observed several occasions in which a pest control technician documented interior stations with apparent rodent activity, including inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room, \u003Cstrong>(b)(4)\u003C\u002Fstrong> room where finished products are stored, and in the ambient warehouse. In addition, our investigator observed multiple exit doors propped open to the outside.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During the inspection, you stated that you would create a risk assessment based on your assessment of these observations and that you were already in the process of making certain changes, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will evaluate the adequacy of your corrective actions during our next inspection.\u003C\u002Fp>\u003Cp>2. Your quality control personnel failed to approve or reject all processes, specifications, written procedures, controls, tests, and examinations, and deviations from or modifications to them, that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>Your component specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong> had not been signed and approved by your quality control personnel.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that your raw material specifications will be signed, reviewed, and approved by quality control personnel. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your quality control personnel have approved your raw material specifications.\u003C\u002Fp>\u003Cp>3. Your written batch production records (BPRs) did not include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b), because they did not include all information required to be in a BPR under 21 CFR 111.260. Specifically, your firm’s BPRs for the dietary supplement products Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell did not include the following required information:\u003C\u002Fp>\u003Cul>\u003Cli>The time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained. [21 CFR 111.260(c)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for weighing or measuring each component used in the batch. [21 CFR 111.260(j)(2)(i)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for verifying the weight or measure of each component used in the batch. [21 CFR 111.260(j)(2)(ii)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for adding the component to the batch. [21 CFR 111.260(j)(2)(iii)]\u003C\u002Fli>\u003Cli>The initials of the person responsible for verifying the addition of components to the batch. [21 CFR 111.260(j)(2)(iv)].\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that the batch production records will be updated. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your batch production records have been updated.\u003C\u002Fp>\u003Cp>4. Your firm failed to qualify certain suppliers by establishing the reliability of the suppliers’ certificates of analyses through confirmation of the results of the suppliers’ tests or examinations, in accordance with 21 CFR 111.75(a)(2)(ii)(A). Specifically, your firm relies on certificates of analyses to determine that component specifications for identity, purity, strength, composition, and limits on contamination are met, and you did not conduct testing on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary ingredients to establish the reliability of the suppliers’ certificates of analyses before use.\u003C\u002Fp>\u003Cp>We have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated, “suppliers will be qualified establishing the reliability of the supplier’s certification of analysis through confirmation of the results of their tests or examinations.” On May 1, 2026, you provided component specification sheets that include instructions to confirm suppliers’ certificates of analyses with testing; however, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that the relevant suppliers have been qualified.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>We also have the following comment:\u003C\u002Fp>\u003Cp>21 CFR 111.75(a)(2) does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient. Rather, under 21 CFR 111.75(a)(1)(i), you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, prior to using a component (or submit an exemption petition under 21 CFR 111.75(a)(2)(ii)). However, your component specification sheets submitted on May 1, 2026, for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> dietary ingredients state that component identity testing will be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> instead of every time the component is used.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #724745 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luke C. Blotsky\n\nRecipient Title\n\nCEO\n\nMineral BioSciences, LLC\n\n4050 S Sarival Ave\n\nGoodyear, AZ 85338-3233\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJune 5, 2026\nWARNING LETTER\nCMS #724745\nDear Mr. Blotsky:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4050 S Sarival Ave, Goodyear, AZ, on November 12-24, 2025. Based on inspectional findings and subsequent review of your websites https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F, and your Facebook and Instagram social media pages at https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F and https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on November 24, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated December 18, 2025, April 13, 2026, April 30, 2026, and May 1, 2026, and we address your responses below.\nUnapproved New Drugs\nFDA reviewed your websites at the Internet addresses https:\u002F\u002Fmineralbiosciences.com\u002F and https:\u002F\u002Fprotectcells.com\u002F in May 2026 and determined that you take orders on the website https:\u002F\u002Fprotectcells.com\u002F for your products Totala Fulvic Ionic Mineral Complex and Ionicell. We also reviewed your social media pages on Facebook (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F) and Instagram (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F) in March 2026, where you direct consumers to your website, https:\u002F\u002Fprotectcells.com\u002F, to purchase your products. Claims on your social media webpages establish that your Totala Fulvic Ionic Mineral Complex and Ionicell products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\nTotala Fulvic Ionic Mineral Complex AND Ionicell\n“Did you know Higher A1C levels are linked to diabetes complications? But did you also know that case reports have shown that Ioniplex can help control post-prandial blood sugar levels?” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated February 24, 2022)\nTotala Fulvic Ionic Mineral Complex AND Ionicell\n“Ioniplex has been clinically shown to repair and stimulate the body at the cellular level, leading to better glucose management.” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https:\u002F\u002Fwww.facebook.com\u002FProtectCells\u002F, from a post dated January 29, 2021)\nTotala Fulvic Ionic Mineral Complex\n“[H]as been taking Totala … and has noticed not only a drop in his blood pressure, but less pain in his joints…” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 23, 2018)\nIonicell\n“[H]as been taking IoniCell for several weeks and has already noticed a drop in her daily glucose levels and fasting glucose levels.” (https:\u002F\u002Fwww.instagram.com\u002Fp\u002FBYR6AmlDlx4\u002F, from a post dated February 6, 2018)\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drugs\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour products Totala Fulvic Ionic Mineral Complex and Ionicell are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Totala Fulvic Ionic Mineral Complex and Ionicell fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\nAdulterated Dietary Supplements\nThe inspection of your facility on November 12-24, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Thus, in addition to being unapproved new drugs and misbranded drugs, your Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell products are also adulterated dietary supplements under section 402(g)(1) of the Act.\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to meet sanitation requirements that apply to your physical plant and grounds under 21 CFR 111.15. Specifically:\nYou failed to maintain your physical plant in a clean and sanitary condition and in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated, as required by 21 CFR 111.15(b). For example, from November 12-13, 2025, our investigator observed insulation hanging from the ceiling, one light casing which appeared to be taped with water leaking from it, two holes in your wall exposing outside elements, and multiple doors, including bay doors, with opening gaps allowing light to shine into your facility.\nYou failed to take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests, as required by 21 CFR 111.15(d)(2). For example, on November 13, 2025, our investigator reviewed your pest control records for April 2025 through November 2025 and observed several occasions in which a pest control technician documented interior stations with apparent rodent activity, including inside the (b)(4) room, (b)(4) room where finished products are stored, and in the ambient warehouse. In addition, our investigator observed multiple exit doors propped open to the outside.\nDuring the inspection, you stated that you would create a risk assessment based on your assessment of these observations and that you were already in the process of making certain changes, such as (b)(4). We will evaluate the adequacy of your corrective actions during our next inspection.\n2. Your quality control personnel failed to approve or reject all processes, specifications, written procedures, controls, tests, and examinations, and deviations from or modifications to them, that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically:\nYour component specifications for (b)(4) had not been signed and approved by your quality control personnel.\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that your raw material specifications will be signed, reviewed, and approved by quality control personnel. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your quality control personnel have approved your raw material specifications.\n3. Your written batch production records (BPRs) did not include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b), because they did not include all information required to be in a BPR under 21 CFR 111.260. Specifically, your firm’s BPRs for the dietary supplement products Totala Fulvic Ionic Mineral Complex Lemon Lime and Ionicell did not include the following required information:\nThe time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained. [21 CFR 111.260(c)]\nThe initials of the person responsible for weighing or measuring each component used in the batch. [21 CFR 111.260(j)(2)(i)]\nThe initials of the person responsible for verifying the weight or measure of each component used in the batch. [21 CFR 111.260(j)(2)(ii)]\nThe initials of the person responsible for adding the component to the batch. [21 CFR 111.260(j)(2)(iii)]\nThe initials of the person responsible for verifying the addition of components to the batch. [21 CFR 111.260(j)(2)(iv)].\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated that the batch production records will be updated. However, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that your batch production records have been updated.\n4. Your firm failed to qualify certain suppliers by establishing the reliability of the suppliers’ certificates of analyses through confirmation of the results of the suppliers’ tests or examinations, in accordance with 21 CFR 111.75(a)(2)(ii)(A). Specifically, your firm relies on certificates of analyses to determine that component specifications for identity, purity, strength, composition, and limits on contamination are met, and you did not conduct testing on your (b)(4) dietary ingredients to establish the reliability of the suppliers’ certificates of analyses before use.\nWe have reviewed your responses to the FDA 483, dated December 18, 2025, and April 30, 2026, in which you stated, “suppliers will be qualified establishing the reliability of the supplier’s certification of analysis through confirmation of the results of their tests or examinations.” On May 1, 2026, you provided component specification sheets that include instructions to confirm suppliers’ certificates of analyses with testing; however, we are unable to evaluate the adequacy of your response because you did not provide documentation supporting that the relevant suppliers have been qualified.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nWe also have the following comment:\n21 CFR 111.75(a)(2) does not allow firms to rely on a certificate of analysis to confirm the identity of a dietary ingredient. Rather, under 21 CFR 111.75(a)(1)(i), you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, prior to using a component (or submit an exemption petition under 21 CFR 111.75(a)(2)(ii)). However, your component specification sheets submitted on May 1, 2026, for your (b)(4) dietary ingredients state that component identity testing will be conducted (b)(4) instead of every time the component is used.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #724745 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Mineral BioSciences, LLC","mineral-biosciences-llc-724745-06052026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmineral-biosciences-llc-724745-06052026","2026-10-26T08:09:26.032125+00:00","2026-07-21","724745","Mr. Luke C. Blotsky","2026-08-19T04:29:08.005+00:00","2026-06-05",{"id":207,"raw":208,"subject":212,"body_html":213,"body_text":214,"firm_name":215,"letter_id":216,"created_at":176,"fei_number":19,"letter_url":217,"updated_at":218,"action_type":22,"case_status":23,"posted_date":219,"marcs_cms_no":220,"product_type":92,"closeout_date":19,"issuing_office":82,"recipient_name":221,"body_fetched_at":222,"delivery_method":223,"recipient_title":19,"reference_number":224,"action_taken_date":225,"medical_device_id":19,"response_letter_date":19},3164,[209,210,211,82,212,13,13,13],"\u003Ctime datetime=\"2021-09-07T13:20:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-26T04:00:00Z\">08\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkaleido-biosciences-inc-616026-08262021\">Kaleido Biosciences, Inc.\u003C\u002Fa>","Bioresearch Monitoring Program","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>21-HFD-45-08-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Daniel Menichella\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kaleido Biosciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>65 Hayden Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lexington\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02421-7994\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref: 21-HFD-45-08-01\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Menichella:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted from February 24 to March 3, 2021. Investigator Kent A. Conforti, representing FDA, reviewed the role of Kaleido Biosciences, Inc. (Kaleido) as the sponsor of the following clinical investigations of the investigational drug KB109:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol K031-120: “A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19”\u003C\u002Fli>\n\t\u003Cli>Protocol K032-120: “An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Conforti presented and discussed with your staff the Form FDA 483, Inspectional Observations. We acknowledge our receipt of Kaleido’s March 23, 2021, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and Kaleido’s March 23, 2021, written response to the Form FDA 483, it appears that Kaleido did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to submit INDs for the conduct of clinical investigations with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an investigational new drug application (IND) before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2 (see 21 CFR 312.20 and 312.40(a)). Kaleido failed to comply with these requirements. Specifically, Kaleido initiated and conducted the following clinical investigations of investigational drug products subject to section 505 of the FD&amp;C Act without submitting and having in effect an IND\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The clinical investigation of the investigational drug KB109 conducted under Protocol K031-120\u003C\u002Fli>\n\t\u003Cli>The clinical investigation of the investigational drug KB109 conducted under Protocol K032-120\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In Kaleido’s March 23, 2021, written response to the Form FDA 483, Kaleido argued that it was not obligated to submit an IND before initiating these clinical investigations because the article under study, KB109, was a food rather than a drug. Specifically, Kaleido argued that the investigations were conducted “to evaluate the effect of KB109 on the microbiome[,] as well as to determine the safety and tolerability of KB109 in the diseased population[,]” that is, human subjects with mild to moderate COVID-19, and thus it investigated KB109 for use as a food rather than a drug.\u003C\u002Fp>\n\n\u003Cp>To support this argument, Kaleido asserted that it did not intend for these “food studies” to evaluate whether KB109 would be an effective treatment or mitigation for COVID-19; rather, Kaleido argued that the secondary endpoints in these studies were determinative of safety and tolerability. For this reason, Kaleido stated that KB109 was a food intervention, and consistent with Agency guidance, it was appropriate to conduct these studies without an IND in a population with COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In further discussing the purported safety and tolerability endpoints of these two studies, Kaleido stated that because the medical community was still learning about risk factors for severe COVID-19, signs and symptoms of the disease were collected in both studies to support adequate safety monitoring, in order to capture signals of disease worsening that may warrant referral to emergency medical care. Kaleido argued that it collected information on symptoms related to worsening or improvement of disease conditions to determine if KB109 would have an impact on safety or tolerability in patients with COVID-19.\u003C\u002Fp>\n\n\u003Cp>Kaleido stated that the FD&amp;C Act specifically recognizes products used in the dietary management of a disease and subject to regulation as medical foods (when such products meet the definition of a medical food, comply with the requirements for medical foods, and are not subject to regulation as drugs). Although Kaleido did not explicitly argue that the clinical investigations were exempt from the IND requirement because they studied KB109 for use as a medical food, it did state that the findings from these studies could “enhance our understanding of the distinct nutritional requirements (DNR) that may exist in individuals with respiratory viral illnesses such as COVID-19 and would support the positioning of KB109 as a medical food.”\u003C\u002Fp>\n\n\u003Cp>In further arguing that its clinical investigations studied KB109’s use as a food, Kaleido stated that the Generally Recognized as Safe (GRAS) status of KB109 was determined by an outside firm that evaluated not only the composition of KB109, but also its consumption safety in patients with mild to moderate COVID-19. Kaleido asserted that this GRAS determination supported its conclusion that KB109 is a lawfully marketed food ingredient that could be evaluated in food studies such as Protocols K031-120 and K032-120.\u003C\u002Fp>\n\n\u003Cp>Finally, Kaleido stated that subjects were instructed to follow the Centers for Disease Control and Prevention (CDC) guidelines and supportive self-care (SSC) measures to manage COVID-19 symptoms, and argued that KB109 therefore was given for nutritional purposes and was not studied as a COVID-19 treatment.\u003C\u002Fp>\n\n\u003Cp>For the reasons described below, we conclude that the evidence collected during the inspection shows that KB109 was intended for use as a drug, not as a food, in the two clinical investigations named above.\u003C\u002Fp>\n\n\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines \u003Cem>drug\u003C\u002Fem> as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals . . . .” Kaleido studied the efficacy and safety of KB109 to mitigate and treat COVID-19 in subjects who tested positive for COVID-19 as described below:\u003C\u002Fp>\n\n\u003Cp>As shown by the protocol, a published article supported by Kaleido, and Kaleido’s press releases, the objective of Protocol K031-120 was to compare the safety and efficacy of KB109 in combination with SSC under quarantine protocols set forth by the CDC, with SSC alone in human subjects with mild-to-moderate COVID-19. This study evaluated efficacy endpoints intended to assess KB109 for use in mitigating or treating COVID-19, including change from baseline in, and time to resolution of, overall composite and individual COVID-19-related symptom scores; time to resolution of fever; proportion of subjects with oxygen saturation &lt;95% and &lt;98%; and other endpoints, such as change from baseline in bedrest time, individual measures of quality of life (QOL), proportion of subjects with improvements in patient global impression on COVID-19 condition, proportion of subjects experiencing hospital admissions (all-cause and COVID-19-related), and number of healthcare utilizations.\u003C\u002Fp>\n\n\u003Cp>As shown by the protocol and a published article supported by Kaleido, the objective of Protocol K032-120 was to compare KB109, in combination with SSC under quarantine protocols set forth by the CDC or local ordinances and practices as advised by a healthcare provider, against SSC alone in human subjects with mild-to-moderate COVID-19. Physiologic effects were assessed by measuring biomarkers of inflammation and antibodies, physiologic responses of health in subjects, QOL, and hospital utilization. This study also assessed the effects of KB109 on the gut microbiome structure and function, and evaluated endpoints related to measures of health, as well as changes in laboratory measures, specific biomarkers, serology, and viral load in the presence and absence of KB109.\u003C\u002Fp>\n\n\u003Cp>For Protocol K031-120, the endpoints characterized in the protocol as secondary endpoints (for example, time to resolution of individual and composite COVID-19 symptoms, time to resolution of fever, and proportion of subjects hospitalized) clearly assessed the impact of KB109 on clinical manifestations of COVID-19 and were aligned with the recommended efficacy endpoints in published FDA guidances to aid sponsors in developing products to treat patients with COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4, 5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>For Protocol K032-120, while some endpoints could be considered safety outcomes that might be evaluated only to ensure that treatment with KB109 was not worsening the course of COVID-19, other endpoints (for example, proportion of subjects experiencing hospital admission during the follow-up period, measures of healthcare utilization, and proportion of subjects with oxygen saturation below normal) clearly assessed the use of KB109 in combination with SCC for the treatment or mitigation of COVID-19.\u003C\u002Fp>\n\n\u003Cp>We note that Kaleido itself described the purpose of KB109 in the clinical investigations conducted under Protocols K031-120 and K032-120 as “treatment of mild to moderate COVID-19” in a communication to FDA.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>To the extent that Kaleido intended to argue that KB109 was used as a medical food in these clinical investigations, this argument fails for the following reasons:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A product is a medical food if it is “a food . . . intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> No such distinctive nutritional requirements have been established for COVID-19. Dietary management of a disease is one way to treat or mitigate that disease; therefore, to the extent that a product that does not meet the medical food definition is intended for the dietary management of a disease, it is a drug under section 201(g)(1)(B) of the FD&amp;C Act.\u003C\u002Fli>\n\t\u003Cli>Even if there were distinctive nutritional requirements established for COVID-19, Protocols K031-120 and K032-120 went beyond “dietary management” of COVID-19 to evaluate KB109’s ability to treat COVID-19 by measuring the investigational product’s effects on fever, oxygen saturation, viral load, and other biomarkers of COVID-19 infection, among other things.\u003C\u002Fli>\n\t\u003Cli>Finally, the purported GRAS status of an article for one or more uses in food does not exempt the article from IND requirements when it is studied for use as a drug. In other words, an article may be a drug as used in a clinical trial, even if it is considered a food as used in other contexts. In addition, the instruction for subjects to adhere to CDC guidelines and SSC measures does not preclude investigating KB109 as an add-on therapy in the management of COVID-19 for subjects who are not at high risk for disease worsening or hospitalization.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>As Kaleido noted in its response to the Form FDA 483, whether an investigational article is a drug or a food depends on the intent of the investigation. Based on the study designs of Protocols K031-120 and K032-120, KB109 as used in these clinical investigations was a drug, per 201(g)(1) of the FD&amp;C Act, because KB109 was studied for use in the mitigation and treatment of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Thus, before initiating the clinical investigations of KB109 conducted under Protocol K031- 120 and Protocol K032-120, Kaleido was required to submit an IND to FDA and to have an IND in effect under 21 CFR 312.40. FDA’s records indicate that Kaleido failed to submit an IND before conducting these clinical investigations, in which 350 human subjects were randomized at 16 clinical sites for Protocol K031-120, and 49 human subjects were randomized at 7 clinical sites for Protocol K032-120.\u003C\u002Fp>\n\n\u003Cp>In its response to the Form FDA 483, Kaleido stated that it is developing a procedure for determining the need for an IND (in consultation with FDA) when developing protocols for clinical studies in a disease population where endpoints may be viewed as diagnosing, mitigating, treating, preventing, or curing a disease. Kaleido’s corrective action plan does not provide sufficient details about its new procedure for IND determination. Without these details, we are unable to determine whether Kaleido’s corrective action plan is adequate to prevent similar violations in the future.\u003Cbr>\n\u003Cbr>\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S., RAC (US)\u003Cbr>\nBranch Chief (Acting)\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5219\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Coronavirus Disease 2019 (COVID-19) is the respiratory disease caused by the novel coronavirus called \u003Cem>Severe Acute Respiratory Syndrome Coronavirus 2\u003C\u002Fem> (SARS-CoV-2).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Also, neither of these clinical investigations qualified for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND, September 2013\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Guidance for industry \u003Cem>COVID-19: Developing Drugs and Biological Products for Treatment or Prevention\u003C\u002Fem> (May 2020; updated February 2021).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Guidance for industry \u003Cem>Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment \u003C\u002Fem>(September 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Pre-IND 151218 Type B Meeting Package for KB109, Kaleido Biosciences, Inc. (July 2, 2020).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> 21 U.S.C. 360ee(b)(3).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\n21-HFD-45-08-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDaniel Menichella\n\nRecipient Title\n\nChief Executive Officer\n\nKaleido Biosciences, Inc.\n\n65 Hayden Avenue\n\nLexington, MA 02421-7994\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRef: 21-HFD-45-08-01\n\nDear Mr. Menichella:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted from February 24 to March 3, 2021. Investigator Kent A. Conforti, representing FDA, reviewed the role of Kaleido Biosciences, Inc. (Kaleido) as the sponsor of the following clinical investigations of the investigational drug KB109:\n\nProtocol K031-120: “A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-191 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients with Mild-to-Moderate COVID-19”\n\nProtocol K032-120: “An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients with Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting”\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Conforti presented and discussed with your staff the Form FDA 483, Inspectional Observations. We acknowledge our receipt of Kaleido’s March 23, 2021, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and Kaleido’s March 23, 2021, written response to the Form FDA 483, it appears that Kaleido did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\n\nFailure to submit INDs for the conduct of clinical investigations with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\n\nFDA regulations require a sponsor to submit, and to have in effect, an investigational new drug application (IND) before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2 (see 21 CFR 312.20 and 312.40(a)). Kaleido failed to comply with these requirements. Specifically, Kaleido initiated and conducted the following clinical investigations of investigational drug products subject to section 505 of the FD&C Act without submitting and having in effect an IND2:\n\nThe clinical investigation of the investigational drug KB109 conducted under Protocol K031-120\n\nThe clinical investigation of the investigational drug KB109 conducted under Protocol K032-120\n\nIn Kaleido’s March 23, 2021, written response to the Form FDA 483, Kaleido argued that it was not obligated to submit an IND before initiating these clinical investigations because the article under study, KB109, was a food rather than a drug. Specifically, Kaleido argued that the investigations were conducted “to evaluate the effect of KB109 on the microbiome[,] as well as to determine the safety and tolerability of KB109 in the diseased population[,]” that is, human subjects with mild to moderate COVID-19, and thus it investigated KB109 for use as a food rather than a drug.\n\nTo support this argument, Kaleido asserted that it did not intend for these “food studies” to evaluate whether KB109 would be an effective treatment or mitigation for COVID-19; rather, Kaleido argued that the secondary endpoints in these studies were determinative of safety and tolerability. For this reason, Kaleido stated that KB109 was a food intervention, and consistent with Agency guidance, it was appropriate to conduct these studies without an IND in a population with COVID-19.3\n\nIn further discussing the purported safety and tolerability endpoints of these two studies, Kaleido stated that because the medical community was still learning about risk factors for severe COVID-19, signs and symptoms of the disease were collected in both studies to support adequate safety monitoring, in order to capture signals of disease worsening that may warrant referral to emergency medical care. Kaleido argued that it collected information on symptoms related to worsening or improvement of disease conditions to determine if KB109 would have an impact on safety or tolerability in patients with COVID-19.\n\nKaleido stated that the FD&C Act specifically recognizes products used in the dietary management of a disease and subject to regulation as medical foods (when such products meet the definition of a medical food, comply with the requirements for medical foods, and are not subject to regulation as drugs). Although Kaleido did not explicitly argue that the clinical investigations were exempt from the IND requirement because they studied KB109 for use as a medical food, it did state that the findings from these studies could “enhance our understanding of the distinct nutritional requirements (DNR) that may exist in individuals with respiratory viral illnesses such as COVID-19 and would support the positioning of KB109 as a medical food.”\n\nIn further arguing that its clinical investigations studied KB109’s use as a food, Kaleido stated that the Generally Recognized as Safe (GRAS) status of KB109 was determined by an outside firm that evaluated not only the composition of KB109, but also its consumption safety in patients with mild to moderate COVID-19. Kaleido asserted that this GRAS determination supported its conclusion that KB109 is a lawfully marketed food ingredient that could be evaluated in food studies such as Protocols K031-120 and K032-120.\n\nFinally, Kaleido stated that subjects were instructed to follow the Centers for Disease Control and Prevention (CDC) guidelines and supportive self-care (SSC) measures to manage COVID-19 symptoms, and argued that KB109 therefore was given for nutritional purposes and was not studied as a COVID-19 treatment.\n\nFor the reasons described below, we conclude that the evidence collected during the inspection shows that KB109 was intended for use as a drug, not as a food, in the two clinical investigations named above.\n\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals . . . .” Kaleido studied the efficacy and safety of KB109 to mitigate and treat COVID-19 in subjects who tested positive for COVID-19 as described below:\n\nAs shown by the protocol, a published article supported by Kaleido, and Kaleido’s press releases, the objective of Protocol K031-120 was to compare the safety and efficacy of KB109 in combination with SSC under quarantine protocols set forth by the CDC, with SSC alone in human subjects with mild-to-moderate COVID-19. This study evaluated efficacy endpoints intended to assess KB109 for use in mitigating or treating COVID-19, including change from baseline in, and time to resolution of, overall composite and individual COVID-19-related symptom scores; time to resolution of fever; proportion of subjects with oxygen saturation \u003C95% and \u003C98%; and other endpoints, such as change from baseline in bedrest time, individual measures of quality of life (QOL), proportion of subjects with improvements in patient global impression on COVID-19 condition, proportion of subjects experiencing hospital admissions (all-cause and COVID-19-related), and number of healthcare utilizations.\n\nAs shown by the protocol and a published article supported by Kaleido, the objective of Protocol K032-120 was to compare KB109, in combination with SSC under quarantine protocols set forth by the CDC or local ordinances and practices as advised by a healthcare provider, against SSC alone in human subjects with mild-to-moderate COVID-19. Physiologic effects were assessed by measuring biomarkers of inflammation and antibodies, physiologic responses of health in subjects, QOL, and hospital utilization. This study also assessed the effects of KB109 on the gut microbiome structure and function, and evaluated endpoints related to measures of health, as well as changes in laboratory measures, specific biomarkers, serology, and viral load in the presence and absence of KB109.\n\nFor Protocol K031-120, the endpoints characterized in the protocol as secondary endpoints (for example, time to resolution of individual and composite COVID-19 symptoms, time to resolution of fever, and proportion of subjects hospitalized) clearly assessed the impact of KB109 on clinical manifestations of COVID-19 and were aligned with the recommended efficacy endpoints in published FDA guidances to aid sponsors in developing products to treat patients with COVID-19.4, 5\n\nFor Protocol K032-120, while some endpoints could be considered safety outcomes that might be evaluated only to ensure that treatment with KB109 was not worsening the course of COVID-19, other endpoints (for example, proportion of subjects experiencing hospital admission during the follow-up period, measures of healthcare utilization, and proportion of subjects with oxygen saturation below normal) clearly assessed the use of KB109 in combination with SCC for the treatment or mitigation of COVID-19.\n\nWe note that Kaleido itself described the purpose of KB109 in the clinical investigations conducted under Protocols K031-120 and K032-120 as “treatment of mild to moderate COVID-19” in a communication to FDA.6\n\nTo the extent that Kaleido intended to argue that KB109 was used as a medical food in these clinical investigations, this argument fails for the following reasons:\n\nA product is a medical food if it is “a food . . . intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”7 No such distinctive nutritional requirements have been established for COVID-19. Dietary management of a disease is one way to treat or mitigate that disease; therefore, to the extent that a product that does not meet the medical food definition is intended for the dietary management of a disease, it is a drug under section 201(g)(1)(B) of the FD&C Act.\n\nEven if there were distinctive nutritional requirements established for COVID-19, Protocols K031-120 and K032-120 went beyond “dietary management” of COVID-19 to evaluate KB109’s ability to treat COVID-19 by measuring the investigational product’s effects on fever, oxygen saturation, viral load, and other biomarkers of COVID-19 infection, among other things.\n\nFinally, the purported GRAS status of an article for one or more uses in food does not exempt the article from IND requirements when it is studied for use as a drug. In other words, an article may be a drug as used in a clinical trial, even if it is considered a food as used in other contexts. In addition, the instruction for subjects to adhere to CDC guidelines and SSC measures does not preclude investigating KB109 as an add-on therapy in the management of COVID-19 for subjects who are not at high risk for disease worsening or hospitalization.\n\nAs Kaleido noted in its response to the Form FDA 483, whether an investigational article is a drug or a food depends on the intent of the investigation. Based on the study designs of Protocols K031-120 and K032-120, KB109 as used in these clinical investigations was a drug, per 201(g)(1) of the FD&C Act, because KB109 was studied for use in the mitigation and treatment of COVID-19.\n\nThus, before initiating the clinical investigations of KB109 conducted under Protocol K031- 120 and Protocol K032-120, Kaleido was required to submit an IND to FDA and to have an IND in effect under 21 CFR 312.40. FDA’s records indicate that Kaleido failed to submit an IND before conducting these clinical investigations, in which 350 human subjects were randomized at 16 clinical sites for Protocol K031-120, and 49 human subjects were randomized at 7 clinical sites for Protocol K032-120.\n\nIn its response to the Form FDA 483, Kaleido stated that it is developing a procedure for determining the need for an IND (in consultation with FDA) when developing protocols for clinical studies in a disease population where endpoints may be viewed as diagnosing, mitigating, treating, preventing, or curing a disease. Kaleido’s corrective action plan does not provide sufficient details about its new procedure for IND determination. Without these details, we are unable to determine whether Kaleido’s corrective action plan is adequate to prevent similar violations in the future.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nWithin 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S., RAC (US)\n\nBranch Chief (Acting)\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5219\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n\u002FS\u002F\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________\n\n1 Coronavirus Disease 2019 (COVID-19) is the respiratory disease caused by the novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\n\n2 Also, neither of these clinical investigations qualified for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312.\n\n3 Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND, September 2013.\n\n4 Guidance for industry COVID-19: Developing Drugs and Biological Products for Treatment or Prevention (May 2020; updated February 2021).\n\n5 Guidance for industry Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment (September 2020).\n\n6 Pre-IND 151218 Type B Meeting Package for KB109, Kaleido Biosciences, Inc. (July 2, 2020).\n\n7 21 U.S.C. 360ee(b)(3).","Kaleido Biosciences, Inc.","kaleido-biosciences-inc-616026-08262021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkaleido-biosciences-inc-616026-08262021","2026-10-26T08:09:07.576596+00:00","2021-09-07","616026","Daniel Menichella","2026-08-20T02:37:45.127+00:00","VIA UPS and Electronic Mail","21-HFD-45-08-01","2021-08-26",{"id":227,"raw":228,"subject":37,"body_html":233,"body_text":234,"firm_name":235,"letter_id":236,"created_at":176,"fei_number":19,"letter_url":237,"updated_at":238,"action_type":22,"case_status":23,"posted_date":239,"marcs_cms_no":240,"product_type":92,"closeout_date":19,"issuing_office":232,"recipient_name":241,"body_fetched_at":242,"delivery_method":185,"recipient_title":19,"reference_number":19,"action_taken_date":243,"medical_device_id":19,"response_letter_date":19},3457,[229,230,231,232,37,13,13,13],"\u003Ctime datetime=\"2021-03-16T13:20:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-10T05:00:00Z\">03\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffoshan-biours-biosciences-co-ltd-611319-03102021\">Foshan Biours Biosciences Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paul Huang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Foshan Biours Biosciences Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13 East Xile Road, Tower B F1 Complex Bldg.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rooms 201, 202, 203 (2nd Floor) &amp; 302 (3rd Floor)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Foshan Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>528137\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-34\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 10, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Huang:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our April 3, 2020 request, and subsequent requests, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Foshan Biours Biosciences Co., Ltd., FEI 3011474550, at 13 East Xile Road, Tower B F1 Complex Bldg., Rooms 201, 202, 203 (2nd Floor) &amp; 302 (3rd Floor), Foshan, Guangdong.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures an over-the-counter (OTC) drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Patch containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response to our request for records and other information under section 704(a)(4) indicates that you distributed this drug product into the United States without adequate finished drug product testing.\u003C\u002Fp>\n\n\u003Cp>For example, in response to our request to provide release specifications of U.S. products and the test method used to evaluate them, you submitted a certificate of analysis for your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch that shows you did not conduct adequate testing for identity and strength of the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as is required prior to release per 211.165(a). No other information provided was responsive to our request for information about release testing. Your response indicates that you do not perform assay testing for identity and strength of your active ingredient.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States:\u003C\u002Fp>\n\n\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>\n&nbsp; &nbsp;o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the U.S. that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp;o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the information you provided in response to our request for cleaning procedures for cleaning equipment for U.S. product lines, you have not conducted cleaning validation studies. For example, in response to our records request you indicated that there was no validated cleaning procedure for the equipment used in the manufacture and packaging of your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch. Additionally, you stated that the equipment used in the manufacture and packaging of your OTC&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch is not dedicated to that drug product.\u003C\u002Fp>\n\n\u003Cp>Without cleaning validation studies you cannot demonstrate that your cleaning procedures for non-dedicated production equipment are adequate to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States:\u003C\u002Fp>\n\n\u003Cp>• Steps your firm has taken to develop an adequate cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to our request for a list all batches in stability and a list of all stability studies, you did not provide adequate stability data to demonstrate that the chemical properties of your drug products remain acceptable throughout the labeled expiry period. For example, your stability data for OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> Patch does not include testing for the active ingredient. Therefore, the data does not demonstrate that the drug’s active ingredient is stable throughout its shelf life.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following for all drug products imported to the United States:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>\n&nbsp; o Stability indicating methods, including both analytical and microbiological test methods\u003Cbr>\n&nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; o detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>• All procedures that describe these and other elements of your remediated stability program,\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed the drug product manufactured by your firm on Import Alert 66-40 on October 22, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of this violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>Until all violations are addressed completely and we confirm your compliance with CGMP, they may be cause for FDA to withhold approval of any new drug applications or supplements listing your firm as a drug manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011474550 and ATTN: CDR Frank Verni.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC (via email &amp; UPS):\u003Cbr>\nDavid Lennarz, U.S. Agent\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, Virginia 23666\u003Cbr>\ndrugs@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Paul Huang\n\nRecipient Title\n\nGeneral Manager\u002FCEO\n\nFoshan Biours Biosciences Co., Ltd.\n\n13 East Xile Road, Tower B F1 Complex Bldg.\n\nRooms 201, 202, 203 (2nd Floor) & 302 (3rd Floor)\n\nFoshan Shi\n\nGuangdong Sheng, 528137\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-34\n\nMarch 10, 2021\n\nDear Mr. Huang:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our April 3, 2020 request, and subsequent requests, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Foshan Biours Biosciences Co., Ltd., FEI 3011474550, at 13 East Xile Road, Tower B F1 Complex Bldg., Rooms 201, 202, 203 (2nd Floor) & 302 (3rd Floor), Foshan, Guangdong.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210 and 211.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm manufactures an over-the-counter (OTC) drug product, (b)(4) Patch containing (b)(4). Your response to our request for records and other information under section 704(a)(4) indicates that you distributed this drug product into the United States without adequate finished drug product testing.\n\nFor example, in response to our request to provide release specifications of U.S. products and the test method used to evaluate them, you submitted a certificate of analysis for your OTC (b)(4) Patch that shows you did not conduct adequate testing for identity and strength of the active ingredient, (b)(4), as is required prior to release per 211.165(a). No other information provided was responsive to our request for information about release testing. Your response indicates that you do not perform assay testing for identity and strength of your active ingredient.\n\nWithout adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release.\n\nIn response to this letter, provide the following for all drug products imported to the United States:\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the U.S. that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nBased on the information you provided in response to our request for cleaning procedures for cleaning equipment for U.S. product lines, you have not conducted cleaning validation studies. For example, in response to our records request you indicated that there was no validated cleaning procedure for the equipment used in the manufacture and packaging of your OTC (b)(4) Patch. Additionally, you stated that the equipment used in the manufacture and packaging of your OTC (b)(4) Patch is not dedicated to that drug product.\n\nWithout cleaning validation studies you cannot demonstrate that your cleaning procedures for non-dedicated production equipment are adequate to prevent cross-contamination.\n\nIn response to this letter, provide the following for all drug products imported to the United States:\n\n• Steps your firm has taken to develop an adequate cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nIn response to our request for a list all batches in stability and a list of all stability studies, you did not provide adequate stability data to demonstrate that the chemical properties of your drug products remain acceptable throughout the labeled expiry period. For example, your stability data for OTC (b)(4) Patch does not include testing for the active ingredient. Therefore, the data does not demonstrate that the drug’s active ingredient is stable throughout its shelf life.\n\nIn response to this letter, provide the following for all drug products imported to the United States:\n\n• A comprehensive, independent assessment and corrective and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods, including both analytical and microbiological test methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no detailed definition of the specific attributes to be tested at each station (timepoint)\n\n• All procedures that describe these and other elements of your remediated stability program,\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any these violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed the drug product manufactured by your firm on Import Alert 66-40 on October 22, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of this violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nUntil all violations are addressed completely and we confirm your compliance with CGMP, they may be cause for FDA to withhold approval of any new drug applications or supplements listing your firm as a drug manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011474550 and ATTN: CDR Frank Verni.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC (via email & UPS):\n\nDavid Lennarz, U.S. Agent\n\n144 Research Drive\n\nHampton, Virginia 23666\n\ndrugs@registrarcorp.com","Foshan Biours Biosciences Co., Ltd.","foshan-biours-biosciences-co-ltd-611319-03102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffoshan-biours-biosciences-co-ltd-611319-03102021","2026-10-26T08:08:42.810323+00:00","2021-03-16","611319","Mr. Paul Huang","2026-08-20T03:16:25.37+00:00","2021-03-10",{"id":245,"raw":246,"subject":252,"body_html":253,"body_text":254,"firm_name":255,"letter_id":256,"created_at":153,"fei_number":19,"letter_url":257,"updated_at":258,"action_type":22,"case_status":23,"posted_date":259,"marcs_cms_no":260,"product_type":71,"closeout_date":19,"issuing_office":250,"recipient_name":261,"body_fetched_at":262,"delivery_method":263,"recipient_title":19,"reference_number":264,"action_taken_date":265,"medical_device_id":19,"response_letter_date":19},2429,[247,248,249,250,251,13,13,13],"\u003Ctime datetime=\"2022-09-20T13:20:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-23T04:00:00Z\">08\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022\">BioLab Sciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 621465\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert D. Maguire\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioLab Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13825 N. Northsight Blvd., Suite 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 23, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Maguire:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\u003C\u002Fp>\n\n\u003Cp>Because Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deficiencies, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You failed to validate the aseptic processes used to manufacture over&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Fluid Flow™, Amnio Restore™,\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of these products since June 22, 2021.\u003C\u002Fp>\n\n\u003Cp>c. Your Fluid Flow™ \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation, entitled “\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You did not assess the impact of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\u003C\u002Fp>\n\n\u003Cp>d. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel monitoring is required only every \u003Cstrong>(b)(4)\u003C\u002Fstrong> for personnel who process your amniotic fluid products.\u003C\u002Fp>\n\n\u003Cp>e. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\u003C\u002Fp>\n\n\u003Cp>f. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\u003C\u002Fp>\n\n\u003Cp>g. Your written environmental monitoring procedure now describes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca>www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your BSCs.\u003Cbr>\n\u003Cbr>\nb. Your firm has not adequately established and followed written procedures for cleaning the \u003Cstrong>(b)(4)\u003C\u002Fstrong> BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used to clean the BSCs during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your cleanrooms.\u003C\u002Fp>\n\n\u003Cp>b. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. In accordance with your cleanroom cleaning procedure, a \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>cleaning of all contact surfaces in the cleanrooms is required at the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> processing operations. However, a review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You failed to ensure sufficient use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified \u003Cem>Bacillus\u003C\u002Fem>, species, a spore-forming organism, on your cleanroom floors. You noted that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iii. Your written procedure for cleanroom cleaning does not include the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)].\u003C\u002Fstrong> For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its&nbsp;\u003C\u002Fstrong>\u003Cstrong>specifications whether or not the batch has been already distributed [21 CFR 211.192].\u003C\u002Fstrong> For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include \u003Cem>Bacillus\u003C\u002Fem> species non-anthracis, \u003Cem>Fictibacillus\u003C\u002Fem> species, \u003Cem>Bacillus pumilus\u003C\u002Fem>, Gram Positive Cocci, fungi, and \u003Cem>Bacillus megaterium\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\u003C\u002Fp>\n\n\u003Cp>b. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\u003C\u002Fp>\n\n\u003Cp>c. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid Flow™, and Amnio Restore™.\u003C\u002Fp>\n\n\u003Cp>Your responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\u003C\u002Fp>\n\n\u003Cp>We note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\u003C\u002Fp>\n\n\u003Cp>Finally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>Cc: Robert D. Maguire\u003Cbr>\nPresident and Chief Executive Officer\u003Cbr>\nBioLab Sciences, Inc.\u003Cbr>\n7662 East Gray Road, Suite 107\u003Cbr>\nScottsdale, AZ 85260\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Some of your products are the same products marketed under different brand names. For example, you represented to FDA that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\nOBPO 621465\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nRobert D. Maguire\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n13825 N. Northsight Blvd., Suite 101\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 23, 2022\n\nDear Mr. Maguire:\n\nDuring an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).1,2 You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\n\nMyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\n\nBased on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\n\nMyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\n\nAn HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are (b)(4) prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\n\nBecause Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].3\n\nPlease be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and (b)(4), are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&C Act.\n\nIn order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\n\nYour CGMP deficiencies, involving over (b)(4) units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\n\n1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. You failed to validate the aseptic processes used to manufacture over (b)(4) units of Fluid Flow™, Amnio Restore™,(b)(4), Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\n\nb. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over (b)(4) units of these products since June 22, 2021.\n\nc. Your Fluid Flow™ (b)(4) sterilization validation, entitled “(b)(4) Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\n\ni. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\n\nii. You did not assess the impact of the (b)(4) sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\n\nd. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\n\ni. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\n\nii. Personnel monitoring is required only every (b)(4) for personnel who process your amniotic fluid products.\n\ne. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\n\nf. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\n\ng. Your written environmental monitoring procedure now describes that (b)(4) colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\n\n3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your BSCs.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the (b)(4) BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the (b)(4) when (b)(4) is used to clean the BSCs during (b)(4) cleanings.\n\n4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your cleanrooms.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\n\ni. In accordance with your cleanroom cleaning procedure, a (b)(4) cleaning of all contact surfaces in the cleanrooms is required at the (b)(4) processing operations. However, a review of your (b)(4) cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\n\nii. You failed to ensure sufficient use of (b)(4), a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified Bacillus, species, a spore-forming organism, on your cleanroom floors. You noted that (b)(4) was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\n\niii. Your written procedure for cleanroom cleaning does not include the (b)(4) when (b)(4) is used during (b)(4) cleanings.\n\niv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\n\n5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)]. For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\n\n6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed [21 CFR 211.192]. For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include Bacillus species non-anthracis, Fictibacillus species, Bacillus pumilus, Gram Positive Cocci, fungi, and Bacillus megaterium.\n\n7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84]. For example:\n\na. Your firm used (b)(4) to manufacture approximately (b)(4) batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\n\nb. Your firm used (b)(4), to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\n\nc. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\n\n8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\n\nWe have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\n\nWe acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.4 You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing (b)(4), Stimuleyes™, Fluid Flow™, and Amnio Restore™.\n\nYour responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\n\nWe note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\n\nFinally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Robert D. Maguire\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n7662 East Gray Road, Suite 107\n\nScottsdale, AZ 85260\n\n_________________________\n\n1 This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\n\n2 Some of your products are the same products marketed under different brand names. For example, you represented to FDA that (b)(4) is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\n\n3 As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. (b)(4).\n\n4 We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.","BioLab Sciences, Inc.","biolab-sciences-inc-621465-08232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022","2026-10-26T08:08:04.986053+00:00","2022-09-20","621465","Robert D. Maguire","2026-08-20T01:33:07.944+00:00","VIA UNITED PARCEL SERVICE","OBPO 621465","2022-08-23",{"id":267,"raw":268,"subject":273,"body_html":275,"body_text":276,"firm_name":277,"letter_id":278,"created_at":18,"fei_number":19,"letter_url":279,"updated_at":280,"action_type":22,"case_status":113,"posted_date":281,"marcs_cms_no":282,"product_type":26,"closeout_date":283,"issuing_office":272,"recipient_name":284,"body_fetched_at":285,"delivery_method":286,"recipient_title":19,"reference_number":19,"action_taken_date":287,"medical_device_id":19,"response_letter_date":19},2978,[269,270,271,272,273,13,274,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-23T05:00:00Z\">11\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021\">DeVilbiss Healthcare LLC\u003C\u002Fa>","Office of Medical Device and Radiological Health Operations (Division 1)","Medical Device Reporting\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrive-devilbiss-healthcare-llc-619182-10232024\">\u003Ctime datetime=\"2024-10-30T04:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Derek Lampert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DeVilbiss Healthcare LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>99 Seaview Blvd, Suite 210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Washington\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Operations (Division 1)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Lampert:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. &nbsp;During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. &nbsp;Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. &nbsp;We address the responses below, in relation to each of the noted violations. &nbsp;These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). &nbsp;Specifically,\u003C\u002Fp>\n\n\u003Cp>The model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (5°C-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°C). &nbsp;Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We reviewed your responses for this matter and conclude that they are not adequate. &nbsp;In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. &nbsp;You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” &nbsp;Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. &nbsp;This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\u003C\u002Fp>\n\n\u003Cp>Included in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. &nbsp;The \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C ambient temperature is one of the stress factors used in the study. &nbsp;This would demonstrate not that \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Test Protocol and Report.” &nbsp;The test of compressor temperatures ran for a duration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> period that were higher than the manufacturer’s specified temperature for the compressors. &nbsp;The 525 Oxygen Concentrator is typically run for much longer periods of time than only \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulting in possible temperature \u003Cstrong>(b)(4)\u003C\u002Fstrong> that could result in much higher ambient temperatures over time. &nbsp;The test of \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include any definition of a time element in the test method or results. &nbsp;It cannot be determined the duration of the test, or how often data readings were taken.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp; &nbsp;Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” &nbsp;The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. &nbsp;Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. &nbsp;Examples include:&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp;RO_0264829, received on 04\u002F02\u002F2020\u003Cbr>\n­ RO_0252308, received on 1\u002F28\u002F2020\u003Cbr>\n­ RO_0208546, received on 04\u002F05\u002F2019\u003Cbr>\n­ RO_0180765, received on 08\u002F23\u002F2018\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” &nbsp;No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. &nbsp;No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n3.&nbsp;&nbsp; &nbsp;Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is trending in a direction that could lead to a potential undesirable event.” &nbsp;No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> “trending in a direction that could lead to a potential undesirable event.”\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. &nbsp;Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. &nbsp;It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. &nbsp;Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp;&nbsp; &nbsp;Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. &nbsp;The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\u003C\u002Fp>\n\n\u003Cp>5.&nbsp;&nbsp; &nbsp;Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). &nbsp;Specifically, you do not have a written procedure that governs rework for in-process products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. &nbsp;Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR). &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>6.&nbsp;&nbsp; &nbsp;Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). &nbsp;Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. &nbsp;Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements. &nbsp;\u003C\u002Fp>\n\n\u003Cp>7.&nbsp;&nbsp; &nbsp;Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>On 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. &nbsp;These corrective actions are ongoing at this time.\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. &nbsp;Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. &nbsp;These actions include, but are not limited to, seizure, injunction, and civil money penalties. &nbsp;Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. &nbsp;Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. &nbsp;Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. &nbsp;If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. &nbsp;If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive and address all violations included in this Warning Letter.&nbsp;\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. &nbsp;Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. &nbsp;Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nJoseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u003C\u002Fp>\n\n\u003Cp>cc: &nbsp;&nbsp; &nbsp;Joseph Lewarski, Senior Vice President, Clinical Affairs\u003Cbr>\n&nbsp;&nbsp; &nbsp;Tony Sapp, Director, Regulatory Affairs and Audits\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDerek Lampert\n\nRecipient Title\n\nChief Executive Officer\n\nDeVilbiss Healthcare LLC\n\n99 Seaview Blvd, Suite 210\n\nPort Washington, NY 11050\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Operations (Division 1)\n\nUnited States\n\nDear Mr. Lampert:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). Specifically,\n\nThe model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-(b)(4)°F (5°C-(b)(4)°C). Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in (b)(4) of the (b)(4) measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites.\n\nWe reviewed your responses for this matter and conclude that they are not adequate. In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of (b)(4)°C. You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\n\nIncluded in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at (b)(4)°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. The (b)(4)°C ambient temperature is one of the stress factors used in the study. This would demonstrate not that (b)(4)°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.\n\nIn your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “(b)(4) Test Protocol and Report.” The test of compressor temperatures ran for a duration of (b)(4) and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the (b)(4) period that were higher than the manufacturer’s specified temperature for the compressors. The 525 Oxygen Concentrator is typically run for much longer periods of time than only (b)(4), resulting in possible temperature (b)(4) that could result in much higher ambient temperatures over time. The test of (b)(4) did not include any definition of a time element in the test method or results. It cannot be determined the duration of the test, or how often data readings were taken.\n\nPlease provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range.\n\n2. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. Examples include, but are not limited to:\n\n• Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”\n\n• Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. Examples include:\n\nRO_0264829, received on 04\u002F02\u002F2020\n\n­ RO_0252308, received on 1\u002F28\u002F2020\n\n­ RO_0208546, received on 04\u002F05\u002F2019\n\n­ RO_0180765, received on 08\u002F23\u002F2018\n\n• Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\n\n• Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event.\n\n3. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\n\nYour CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that (b)(4) is trending in a direction that could lead to a potential undesirable event.” No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a (b)(4) “trending in a direction that could lead to a potential undesirable event.”\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.\n\nPlease provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\n\n4. Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\n\n• Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\n\n5. Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). Specifically, you do not have a written procedure that governs rework for in-process products.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR).\n\nPlease provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\n\nOur inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\n\n6. Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints.\n\nPlease provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements.\n\n7. Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Specifically,\n\nOn 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4). An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing.\n\nYou also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. These corrective actions are ongoing at this time.\n\nPlease provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nAdditionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002Fs\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\n\ncc: Joseph Lewarski, Senior Vice President, Clinical Affairs\n\nTony Sapp, Director, Regulatory Affairs and Audits","DeVilbiss Healthcare LLC","devilbiss-healthcare-llc-619182-11232021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021","2026-10-26T08:08:23.773628+00:00","2021-12-14","619182","2024-10-30","Derek Lampert","2026-08-20T02:20:42.968+00:00","UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL","2021-11-23",{"id":289,"raw":290,"subject":294,"body_html":295,"body_text":296,"firm_name":297,"letter_id":298,"created_at":87,"fei_number":19,"letter_url":299,"updated_at":300,"action_type":22,"case_status":23,"posted_date":301,"marcs_cms_no":302,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":303,"body_fetched_at":304,"delivery_method":263,"recipient_title":19,"reference_number":19,"action_taken_date":305,"medical_device_id":19,"response_letter_date":19},1534,[291,292,293,11,294,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-21T04:00:00Z\">03\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024\">Agena Bioscience, Inc.\u003C\u002Fa>","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roman Haehn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager of Clinical Genomics\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Agena Bioscience, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4755 Eastgate Mall\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Roman.Haehn@agenabio.com\"> Roman.Haehn@agenabio.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 665159\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 21, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Haehn,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>The evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>You currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\u003C\u002Fp>\n\n\u003Cp>The IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\u003C\u002Fp>\n\n\u003Cp>Based on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Verbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\u003C\u002Fli>\n\t\u003Cli>Distribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\u003C\u002Fli>\n\t\u003Cli>A customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\u003C\u002Fli>\n\t\u003Cli>A copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\u003C\u002Fp>\n\n\u003Cp>Your iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\u003C\u002Fp>\n\n\u003Cp>On June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\u003C\u002Fp>\n\n\u003Cp>We request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney Lias, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director, Division 3\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Glen Wise\u003Cbr>\nDirector, Quality and Regulatory\u003Cbr>\nGlenn.wise@agenabio.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoman Haehn\n\nRecipient Title\n\nVice President and General Manager of Clinical Genomics\n\nAgena Bioscience, Inc.\n\n4755 Eastgate Mall\n\nSan Diego, CA 92121\n\nUnited States\n\nRoman.Haehn@agenabio.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS # 665159\n\nMarch 21, 2024\n\nDear Mr. Haehn,\n\nDuring an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThe evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nYou currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\n\nThe IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\n\nDuring the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\n\nBased on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\n\nVerbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\n\nDistribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\n\nA customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\n\nA copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\n\nYour firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\n\nYour firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\n\nYour firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\n\nYour iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\n\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\n\nOn June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\n\nWe request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney Lias, Ph.D.\n\nActing Director\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director, Division 3\n\nOffice of Medical Device and Radiological Health\n\nOffice of Regulatory Affairs\n\nCC: Glen Wise\n\nDirector, Quality and Regulatory\n\nGlenn.wise@agenabio.com","Agena Bioscience, Inc.","agena-bioscience-inc-665159-03212024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024","2026-10-26T08:07:51.129425+00:00","2024-04-02","665159","Roman Haehn","2026-08-20T00:12:02.998+00:00","2024-03-21",14,{"510k":308,"classification":309,"enforcement":310,"event":311,"event_backfill":312,"pma":313,"warning_letter":314},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]